User Image Cart Icon 0 Search Image

Fatty Liver Obesity

  1. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis
  2. obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
  3. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised …
  4. obesity and nonalcoholic fatty liver disease
  5. Abdominal obesity and fatty liver
  6. obesity and nonalcoholic fatty liver disease: current perspectives
  7. obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
  8. fatty liver disease in morbid obesity
  9. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations
  10. obesity, fatty liver and liver cancer.
  11. obesity is an independent risk factor for non‐alcoholic fatty liver disease: evidence from a meta‐analysis of 21 cohort studies
  12. liver cancer: connections with obesity, fatty liver, and cirrhosis
  13. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
  14. Efficacy of dietary intervention and physical activity in children and adolescents with nonalcoholic fatty liver disease associated with obesity: A scoping review
  15. Prevalence of nonalcoholic fatty liver disease in children with obesity
  16. obesity and the liver: nonalcoholic fatty liver disease
  17. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey
  18. Nonalcoholic fatty liver disease and obesity treatment
  19. Alcohol and obesity: a dangerous association for fatty liver disease
  20. The effects of metabolic status on non‐alcoholic fatty liver disease‐related outcomes, beyond the presence of obesity
  21. obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer
  22. … impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the fatty liver in obesity (FLiO) randomized controlled …
  23. Arterial hypertension, obesity and non-alcoholic fatty liver disease: is there any connection?
  24. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease
  25. fatty liver and its fibrous changes found in simple obesity of children
  26. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease
  27. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index
  28. Evaluation and management of obesity-related nonalcoholic fatty liver disease
  29. Macronutrients and the adipose-liver axis in obesity and fatty liver
  30. obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease
  31. fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease?
  32. Nonalcoholic fatty liver disease and obesity
  33. Early obesity: risk factor for fatty liver disease
  34. … complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease
  35. fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors
  36. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome
  37. Nonalcoholic fatty liver disease and obesity
  38. Drinking and obesity: alcoholic liver disease/nonalcoholic fatty liver disease interactions
  39. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease
  40. The intersection of nonalcoholic fatty liver disease and obesity
  41. Prevalence and risk factors for non-alcoholic fatty liver in children and youth with obesity
  42. obesity-associated nonalcoholic fatty liver disease
  43. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma
  44. Acetaminophen‐induced liver injury in obesity and nonalcoholic fatty liver disease
  45. obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression
  46. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease
  47. Adipose tissue, obesity and non-alcoholic fatty liver disease.
  48. Pediatric fatty liver and obesity: not always just a matter of non-alcoholic fatty liver disease
  49. Association between different animal protein sources and liver status in obese subjects with non-alcoholic fatty liver disease: fatty liver in obesity (FLiO) study
  50. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol-and obesity-induced fatty liver diseases
  51. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease
  52. liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity
  53. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes
  54. obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
  55. obesity, fatty liver disease and intestinal microbiota
  56. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
  57. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery
  58. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?
  59. Nonalcoholic fatty liver disease in individuals with severe obesity
  60. The differential roles of T cells in non-alcoholic fatty liver disease and obesity
  61. Non-alcoholic fatty liver disease and childhood obesity
  62. The obesity epidemic and nonalcoholic fatty liver disease in children
  63. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic obesity Study
  64. Non-alcoholic fatty liver disease (NAFLD) in obesity
  65. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
  66. Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance
  67. Nonalcoholic fatty liver disease and the epidemic of obesity
  68. Molecular mechanisms of fatty liver in obesity
  69. Nonalcoholic fatty liver: the association with metabolic abnormalities, body mass index and central obesity—a population-based study
  70. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity–a longitudinal cohort study
  71. Non-alcoholic fatty liver disease and its relationship with the nutritional status of vitamin A in individuals with class III obesity
  72. Non-alcoholic fatty liver disease and obesity: not all about body mass index
  73. Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity
  74. Severe obesity is associated with liver disease severity in pediatric non‐alcoholic fatty liver disease
  75. Sarcopenic obesity in fatty liver
  76. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease
  77. liver and muscle in morbid obesity: the interplay of fatty liver and insulin resistance
  78. obesity and non-alcoholic fatty liver disease in chronic hepatitis C
  79. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease
  80. The impact of nonalcoholic fatty liver disease on renal function in children with overweight/obesity
  81. Nonalcoholic fatty liver disease relationship with metabolic syndrome in class III obesity individuals
  82. The potential role of prebiotic fibre for treatment and management of non‐alcoholic fatty liver disease and associated obesity and insulin resistance
  83. Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis
  84. Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria
  85. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity
  86. obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease
  87. Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
  88. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity
  89. Thyroid function and the risk of non-alcoholic fatty liver disease in morbid obesity
  90. Increased prevalence of obesity and metabolic syndrome in patients with alcoholic fatty liver disease
  91. obesity and nonalcoholic fatty liver disease: role of oxidative stress
  92. Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice
  93. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease
  94. obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound
  95. CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease
  96. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease
  97. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat
  98. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease
  99. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys …
  100. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications
  101. obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations
  102. Nonalcoholic fatty liver disease is associated with hyperlipidemia and obesity
  103. The association of lipid metabolism and non-alcoholic fatty liver disease in children with obesity
  104. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in …
  105. Association of short sleep duration with obesity, diabetes, fatty liver and behavioral factors in Japanese men
  106. The relationship between serum transaminase activities and fatty liver in children with simple obesity
  107. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium
  108. obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease
  109. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists
  110. Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity
  111. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance
  112. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity?
  113. Non‐alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C‐reactive protein in Hispanics
  114. Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease [S]
  115. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK
  116. Increased selenoprotein p levels in subjects with visceral obesity and nonalcoholic fatty liver disease
  117. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease
  118. Nonalcoholic fatty liver disease without obesity: the problem to be solved
  119. Retinol and α-tocopherol in morbid obesity and nonalcoholic fatty liver disease
  120. Intestinal microbiota modulation in obesity-related non-alcoholic fatty liver disease
  121. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides
  122. Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin …
  123. A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity
  124. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes
  125. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort
  126. Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease
  127. Beneficial effects of phosphatidylcholine on high-fat diet-induced obesity, hyperlipidemia and fatty liver in mice
  128. The impact of obstructive sleep apnea on nonalcoholic fatty liver disease in patients with severe obesity
  129. Per-and polyfluoroalkyl substances and obesity, type 2 diabetes and non-alcoholic fatty liver disease: a review of epidemiologic findings
  130. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults
  131. obesity as the common soil of non‐alcoholic fatty liver disease and diabetes: role of adipokines
  132. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non‐alcoholic fatty liver disease
  133. Maternal obesity programs offspring nonalcoholic fatty liver disease by innate immune dysfunction in mice
  134. obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study
  135. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical …
  136. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians
  137. Intimate association of visceral obesity with non‐alcoholic fatty liver disease in healthy A sians: A case‐control study
  138. Oxidative stress and altered lipid homeostasis in the programming of offspring fatty liver by maternal obesity
  139. Associations among the degree of nonalcoholic fatty liver disease, metabolic syndrome, degree of obesity in children, and parental obesity
  140. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study …
  141. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents
  142. obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver
  143. obesity, fatty liver and liver cancer
  144. Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease
  145. Gut microbiota and clinical disease: obesity and nonalcoholic fatty liver disease
  146. The potential role of iron and copper in pediatric obesity and nonalcoholic fatty liver disease
  147. Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A United Kingdom population-based cohort …
  148. KLF10 deficiency in CD4+ T cells triggers obesity, insulin resistance, and fatty liver
  149. Effect of taurine on the fatty liver of children with simple obesity
  150. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity
  151. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2
  152. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center …
  153. Nonalcoholic fatty liver disease as a comorbidity of childhood obesity
  154. Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease
  155. Physical activity is related to fatty liver marker in obese youth, independently of central obesity or cardiorespiratory fitness
  156. The use of two-dimensional shear wave elastography in people with obesity for the assessment of liver fibrosis in non-alcoholic fatty liver disease
  157. Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation
  158. Overweight and obesity status from the prenatal period to adolescence and its association with non‐alcoholic fatty liver disease in young adults: cohort study
  159. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults
  160. The influence of environmental factors on nonalcoholic fatty liver disease and obesity
  161. Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies
  162. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae
  163. US time-harmonic elastography: detection of liver fibrosis in adolescents with extreme obesity with nonalcoholic fatty liver disease
  164. Low levels of alcohol consumption, obesity, and development of fatty liver with and without evidence of advanced fibrosis
  165. Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver
  166. Metabolically healthy obesity is associated with an increased risk of diabetes independently of nonalcoholic fatty liver disease
  167. High fructose feeding induces copper deficiency in Sprague–Dawley rats: a novel mechanism for obesity related fatty liver
  168. The major green tea polyphenol,(-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat–fed mice
  169. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver …
  170. fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity
  171. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity
  172. Inducible nitric oxide distribution in the fatty liver of a mouse with high fat diet-induced obesity
  173. Metabolically healthy obesity without fatty liver and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies
  174. Transcriptome analysis of anti-fatty liver action by Campari tomato using a zebrafish diet-induced obesity model
  175. Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease
  176. … of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver …
  177. Childhood obesity: a risk factor for non-alcoholic fatty liver disease in adolescence
  178. PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity
  179. Reduced mitochondrial function in obesity-associated fatty liver: SIRT3 takes on the fat
  180. Western diet causes obesity-induced nonalcoholic fatty liver disease development by differentially compromising the autophagic response
  181. Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity
  182. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver …
  183. obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2
  184. … of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and …
  185. Blocking high-fat diet-induced obesity, insulin resistance and fatty liver by overexpression of Il-13 gene in mice
  186. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus
  187. Ethnic disparities in adiposity: focus on non-alcoholic fatty liver disease, visceral, and generalized obesity
  188. … ) and European Association for the Study of obesity (EASO) clinical practice recommendations for the management of non‐alcoholic fatty liver disease: evaluation of …
  189. The obesity and fatty liver Are Reduced by Plant-Derived Pediococcus pentosaceus LP28 in High Fat Diet-Induced Obese Mice
  190. Garlic essential oil protects against obesity-triggered nonalcoholic fatty liver disease through modulation of lipid metabolism and oxidative stress
  191. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity
  192. obesity and fatty liver are prevented by inhibition of the aryl hydrocarbon receptor in both female and male mice
  193. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease
  194. Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer
  195. fatty liver disease and obesity in youth
  196. Low vitamin D status is associated with nonalcoholic fatty liver disease independent of visceral obesity in Korean adults
  197. Nonalcoholic fatty liver disease vs. obesity on the risk of erosive oesophagitis
  198. Antioxidant-upregulated mesenchymal stem cells reduce inflammation and improve fatty liver disease in diet-induced obesity
  199. Single strain probiotics for dyslipidemia, fatty liver, and obesity: A systematic review and meta-analysis
  200. A Review of Non-Alcoholic fatty liver Disease: From obesity to liver Transplant
  201. The roles of obesity and gender on the relationship between metabolic risk factors and non‐alcoholic fatty liver disease in Koreans
  202. obesity and non-alcoholic fatty liver disease: therapeutic options
  203. obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet.
  204. obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease
  205. obesity in children and adolescents: the relation between metabolic syndrome and non-alcoholic fatty–liver disease
  206. Fat mass and obesity-associated gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease
  207. Association between neck circumference and non-alcoholic fatty liver disease in Mexican children and adolescents with obesity
  208. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography/Koroner anjiyografi …
  209. obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
  210. Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity
  211. … expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver …
  212. Relationship between obesity, metabolic syndrome, and nonalcoholic fatty liver disease in the elderly agricultural and fishing population of Taiwan
  213. Lactobacillus acidophilus NS1 attenuates diet-induced obesity and fatty liver
  214. COX‐2‐mediated inflammation in fat is crucial for obesity‐linked insulin resistance and fatty liver
  215. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease
  216. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome
  217. Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin
  218. Nonalcoholic fatty liver disease in Italian children with Down syndrome: prevalence and correlation with obesity-related features
  219. Translational Research Methods in Diabetes, obesity, and Nonalcoholic fatty liver Disease
  220. Metabolic health is more important than obesity in the development of nonalcoholic fatty liver disease: a 4-year retrospective study
  221. Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity
  222. Suspected nonalcoholic fatty liver disease is not associated with vitamin d status in adolescents after adjustment for obesity
  223. Connection of nicotine to diet-induced obesity and non-alcoholic fatty liver disease: cellular and mechanistic insights
  224. obesity and air pollution: global risk factors for pediatric non-alcoholic fatty liver disease
  225. Anti-obesity and fatty liver-preventing activities of Lonicera caerulea in high-fat diet-fed mice
  226. Compound C protects mice from HFD-induced obesity and nonalcoholic fatty liver disease
  227. Abdominal obesity as a predictive factor of nonalcoholic fatty liver disease assessed by ultrasonography and transient elastography in polycystic ovary …
  228. Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease
  229. Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study
  230. obesity-induced lymphocyte hyperresponsiveness to chemokines: a new mechanism of fatty liver inflammation in obese mice
  231. Association of adolescent obesity with nonalcoholic fatty liver disease and related risk factors in Xi’an, China
  232. Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?
  233. Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease
  234. Differential impact of weight loss on nonalcoholic fatty liver resolution in a North American cohort with obesity
  235. Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease
  236. Cutoff points of abdominal obesity indices in screening for non‐alcoholic fatty liver disease in Asians
  237. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease
  238. Effects of mogrosides on high-fat-diet-induced obesity and nonalcoholic fatty liver disease in mice
  239. Protective effects of licochalcone A ameliorates obesity and non-alcoholic fatty liver disease via promotion of the Sirt-1/AMPK pathway in mice fed a high-fat …
  240. Metformin prevents fatty liver and improves balance of white/brown adipose in an obesity mouse model by inducing FGF21
  241. A novel Wistar rat model of obesity-related nonalcoholic fatty liver disease induced by sucrose-rich diet
  242. Rutin suppresses palmitic acids-triggered inflammation in macrophages and blocks high fat diet-induced obesity and fatty liver in mice
  243. Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity
  244. The roles of the gut microbiota and toll-like receptors in obesity and nonalcoholic fatty liver disease
  245. Impacts of types and degree of obesity on non-alcoholic fatty liver disease and related dyslipidemia in Chinese school-age children?
  246. Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men
  247. Lauric acid versus palmitic acid: effects on adipose tissue inflammation, insulin resistance, and non-alcoholic fatty liver disease in obesity
  248. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity
  249. Effects of Angelica dahurica on obesity and fatty liver in mice
  250. Causal Relationship of Non-alcoholic fatty liver Disease with obesity and Insulin Resistance.
  251. Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease
  252. Maternal obesity programs offspring non-alcoholic fatty liver disease through disruption of 24-h rhythms in mice
  253. Nonalcoholic fatty liver disease and cardiovascular risk in children with obesity
  254. Dietary modification dampens liver inflammation and fibrosis in obesity‐related fatty liver disease
  255. High uric acid, reduced glomerular filtration rate and non-alcoholic fatty liver in young people with obesity
  256. Biochemical predictors of early onset non-alcoholic fatty liver disease in young children with obesity
  257. Intracellular role of exchangeable apolipoproteins in energy homeostasis, obesity and non‐alcoholic fatty liver disease
  258. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density …
  259. Astaxanthin restricts weight gain, promotes insulin sensitivity and curtails fatty liver disease in mice fed a obesity-promoting diet
  260. Relationship between nonalcoholic fatty liver disease and vitamin D nutritional status in extreme obesity
  261. The relationship between aquaglyceroporin expression and development of fatty liver in diet-induced obesity and ob/ob mice
  262. The risk of abdominal obesity according to the degree of non-alcoholic fatty liver disease in Korean men
  263. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study
  264. Very low-carbohydrate ketogenic diet for the treatment of severe obesity and associated non-alcoholic fatty liver disease: the role of sex differences
  265. Non-alcoholic fatty liver disease, obesity and other illnesses
  266. Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation …
  267. Xanthohumol improves diet-induced obesity and fatty liver by suppressing sterol regulatory element-binding protein (SREBP) activation
  268. fatty liver in obesity: relation to Doppler perfusion index measurement of the liver
  269. Soy β-conglycinin improves obesity-induced metabolic abnormalities in a rat model of nonalcoholic fatty liver disease
  270. Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease
  271. Euterpe oleracea Mart.-Derived Polyphenols Protect Mice from Diet-Induced obesity and fatty liver by Regulating Hepatic Lipogenesis and Cholesterol …
  272. Early life famine exposure, adulthood obesity patterns and the risk of nonalcoholic fatty liver disease
  273. Circulating iron levels interaction with central obesity on the risk of nonalcoholic fatty liver disease: a case–control study in Southeast China
  274. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity
  275. … index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance
  276. obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer
  277. obesity and hepatotoxins as risk factors for fatty liver disease.
  278. Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk …
  279. Bitter gourd inhibits the development of obesity-associated fatty liver in C57BL/6 mice fed a high-fat diet
  280. … between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non‐alcoholic fatty liver …
  281. Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non‐alcoholic fatty liver disease with none‐to‐mild obesity and liver …
  282. Surgical management of obesity in patients with morbid obesity and nonalcoholic fatty liver disease
  283. Is there an association of vascular disease and atherosclerosis in children and adolescents with obesity and non-alcoholic fatty liver disease?
  284. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity
  285. Role of fatty liver in the association between obesity and reduced hepatic insulin clearance
  286. The Association between Interleukin-6 and Mean Platelet Volume Levels in Central obesity with or without Non-Alcoholic fatty liver Disease
  287. Non-alcoholic fatty liver in children and adolescents with excess weight and obesity
  288. Nonalcoholic fatty liver disease of obesity
  289. Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians
  290. Comparison of abdominal obesity and fatty liver and their association with insulin resistance and metabolic syndrome in Chinese adults
  291. Iron deficiency in patients with nonalcoholic fatty liver disease is associated with obesity, female gender, and low serum hepcidin
  292. Aerobic training performed at ventilatory threshold improves liver enzymes and lipid profile related to non-alcoholic fatty liver disease in adolescents with obesity
  293. Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative …
  294. Outcomes following serial intragastric balloon therapy for obesity and nonalcoholic fatty liver disease in a single centre
  295. Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits
  296. Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease
  297. Loss of hepatic CEACAM1: a unifying mechanism linking insulin resistance to obesity and non-alcoholic fatty liver disease
  298. Curcumin analog CUR5–8 ameliorates nonalcoholic fatty liver disease in mice with high-fat diet-induced obesity
  299. Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet
  300. fatty liver, insulin resistance, and obesity: relationships with increase in coronary artery calcium over time
  301. Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice
  302. Association of the SH2B1 rs7359397 Gene Polymorphism with Steatosis Severity in Subjects with obesity and Non-Alcoholic fatty liver Disease
  303. Non-Alcoholic fatty liver Disease in Cardiac Patients with Overweight and obesity
  304. The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity
  305. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes
  306. High-altitude chronic hypoxia ameliorates obesity-induced non-alcoholic fatty liver disease in mice by regulating mitochondrial and AMPK signaling
  307. The lemon balm extract ALS-L1023 inhibits obesity and nonalcoholic fatty liver disease in female ovariectomized mice
  308. … Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity
  309. … childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity
  310. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway
  311. Age, abdominal obesity, and glycated hemoglobin are associated with carotid atherosclerosis in type 2 diabetes patients with nonalcoholic fatty liver disease
  312. Soya protein β-conglycinin ameliorates fatty liver and obesity in diet-induced obese mice through the down-regulation of PPARγ
  313. obesity, Smoking, and fatty liver disease
  314. Effectiveness of a carbohydrate restricted diet to treat non-alcoholic fatty liver disease in adolescents with obesity: Trial design and methodology
  315. Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome
  316. Mediation of inflammation, obesity and fatty liver disease by advanced glycation endoproducts.
  317. Relation of anthropometric obesity and computed tomography measured nonalcoholic fatty liver disease (from the Multiethnic Study of Atherosclerosis)
  318. Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity
  319. … adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity
  320. Overexpression of superoxide dismutase 3 gene blocks high-fat diet-induced obesity, fatty liver and insulin resistance
  321. … deficiency leads to decreased atherosclerosis, increased white adipose tissue obesity, and non-alcoholic fatty liver disease: a novel mouse model of obesity …
  322. Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1
  323. Effect of obesity on the relationship between nonalcoholic fatty liver disease and glomerular filtration rate
  324. Beneficial effects of red yeast rice on high-fat diet-induced obesity, hyperlipidemia, and fatty liver in mice
  325. Whey protein isolate protects against diet-induced obesity and fatty liver formation
  326. The crosstalk between hypoxia and innate immunity in the development of obesity-related nonalcoholic fatty liver disease
  327. obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota?
  328. liver‐specific suppressor of cytokine signaling‐3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity 1
  329. … Protective Effect of Myristica fragrans Houtt. Extracts Against obesity and Inflammation by Regulating Free fatty Acids Metabolism in Nonalcoholic fatty liver …
  330. Hepatocyte Notch signaling deregulation related to lipid metabolism in women with obesity and nonalcoholic fatty liver
  331. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised …
  332. Nonalcoholic fatty liver disease and age are strong indicators for atherosclerosis in morbid obesity
  333. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase …
  334. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity
  335. FABP4-Cre mediated expression of constitutively active ChREBP protects against obesity, fatty liver, and insulin resistance
  336. Maslinic acid protects against obesity-induced nonalcoholic fatty liver disease in mice through regulation of the Sirt1/AMPK signaling pathway
  337. Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease
  338. … tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity …
  339. I148M variant of PNPLA3 increases the susceptibility to non‐alcoholic fatty liver disease caused by obesity and metabolic disorders
  340. Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease
  341. Therapeutic application of micellar solubilized xanthohumol in a western-type diet-induced mouse model of obesity, diabetes and non-alcoholic fatty liver …
  342. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis
  343. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice
  344. Correction of adipocyte secretion disorders in patients with non-alcoholic fatty liver disease with overweight and obesity
  345. … and microbiota/metabolite-induced epigenetic modifications in the pathogenesis of obesity, metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver …
  346. Impact of time-restricted feeding and dawn-to-sunset fasting on circadian rhythm, obesity, metabolic syndrome, and nonalcoholic fatty liver disease
  347. obesity and nonalcoholic fatty liver disease: metabolic risks and their correction
  348. Phosphorylation of eIF2α signaling pathway attenuates obesity-induced non-alcoholic fatty liver disease in an ER stress and autophagy-dependent manner
  349. fatty liver index is a risk determinant of incident type 2 diabetes in a metabolically healthy population with obesity
  350. Next-generation sequence analysis of genes associated with obesity and nonalcoholic fatty liver disease-related cirrhosis in extreme obesity
  351. Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD)
  352. obesity and fatty liver are ‘grease’for the machinery of hepatic fibrosis
  353. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity
  354. obesity and nonalcoholic fatty liver disease
  355. Visceral obesity and the risk of Barrett’s esophagus in Japanese patients with non-alcoholic fatty liver disease
  356. Serum gamma-glutamyl transpeptidase level and blood pressure in nondrinkers: a possible pathogenetic role of fatty liver in obesity-related hypertension
  357. Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice
  358. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial
  359. obesity and nonalcoholic fatty liver disease
  360. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option
  361. Lipid accumulation product is a predictor of nonalcoholic fatty liver disease in childhood obesity
  362. The Association between SOCS1− 1656G> A Polymorphism, Insulin Resistance and obesity in Nonalcoholic fatty liver Disease (NAFLD) Patients
  363. Perilipin‐2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra‐hepatocyte actions
  364. GADD34-deficient mice develop obesity, nonalcoholic fatty liver disease, hepatic carcinoma and insulin resistance
  365. Decreased serum neuregulin 4 levels associated with non‐alcoholic fatty liver disease in children with obesity
  366. Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment
  367. Microarray technology in the study of obesity and non‐alcoholic fatty liver disease
  368. Effects of obesity reduction on transient elastography–based parameters in pediatric non-alcoholic fatty liver disease
  369. The assessment of nonalcoholic fatty liver disease detected by computed tomography in cases with obesity and overweight
  370. obesity and nonalcoholic fatty liver disease in children
  371. … of high-fat diet-induced obesity by a mixture of red grape extract, soy isoflavone and L-carnitine: implications in cardiovascular and non-alcoholic fatty liver diseases
  372. fatty liver and obesity in university students
  373. Hyperuricemia precedes non-alcoholic fatty liver disease with abdominal obesity moderating this unidirectional relationship: Three longitudinal analyses
  374. obesity Notches up fatty liver
  375. Secretion of recombinant interleukin-22 by engineered Lactobacillus reuteri reduces fatty liver disease in a mouse model of diet-induced obesity
  376. … serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity
  377. Influence of taurin at the degree of internal obesity and severity of visceral fat dysfunction in patients with non-alcoholic fatty liver disease
  378. KLB gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese
  379. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity
  380. … -dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic fatty liver …
  381. Influence of the interaction between abdominal obesity and hypertriglyceridemia on the development of nonalcoholic fatty liver disease
  382. Preventing phosphorylation of sterol regulatory element-binding protein 1a by MAP-kinases protects mice from fatty liver and visceral obesity
  383. … value of serum ferritin in combination with alanine aminotransferase and glucose levels for noninvasive assessment of NAFLD: fatty liver in obesity (FLiO) …
  384. Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia
  385. obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women
  386. A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-. Leiden mice
  387. Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr …
  388. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with …
  389. Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein–apolipoprotein B-100 in obesity
  390. Hepatic artery resistance in children with obesity and fatty liver
  391. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of …
  392. Non-alcoholic fatty liver disease, bulb carotid intima-media thickness and obesity phenotypes: results of a prospective observational study
  393. Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease
  394. Meroterpenoid-rich fraction of an ethanolic extract from Sargassum serratifolium alleviates obesity and non-alcoholic fatty liver disease in high fat-fed C57BL/6J mice
  395. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell …
  396. Biallelic mutations in GPD1 gene in a Chinese boy mainly presented with obesity, insulin resistance, fatty liver, and short stature
  397. Effects of increased systemic inflammation and central obesity on arterial stiffness in patients with nonalcoholic fatty liver disease
  398. Factors governing development of nonalcoholic fatty liver disease and insulin resistance in obesity
  399. Effect of a lifestyle intervention in children with obesity and nonalcoholic fatty liver disease
  400. Antrodia cinnamomea Prevents obesity, Dyslipidemia, and the Derived fatty liver via Regulating AMPK and SREBP Signaling
  401. Hydrodynamic delivery of interleukin 15 gene promotes resistance to high fat diet-induced obesity, fatty liver and improves glucose homeostasis
  402. Genetic control of obesity, glucose homeostasis, dyslipidemia and fatty liver in a mouse model of diet-induced metabolic syndrome
  403. Oat attenuate non-alcoholic fatty liver and obesity via inhibiting lipogenesis in high fat-fed rat
  404. obesity-linked phosphorylation of SIRT1 by casein kinase 2 inhibits its nuclear localization and promotes fatty liver
  405. Late effects of childhood cancer treatment: severe hypertriglyceridaemia, central obesity, non alcoholic fatty liver disease and diabetes as complications of childhood …
  406. Association of obesity and non-alcoholic fatty liver disease with the fecal calprotectin level in children
  407. Nonalcoholic fatty liver Disease in Children with obesity
  408. Serum vitamin D levels are inversely related with non‐alcoholic fatty liver disease independent of visceral obesity in Chinese postmenopausal women
  409. … reflux symptoms in patients with non-alcoholic fatty liver disease associated with serum levels of triglyceride and cholesterol but not simple visceral obesity
  410. Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents
  411. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: the gut and obesity Asia initiative
  412. obesity AS A RISK FACTOR FOR NON-ALCOHOLIC fatty liver DISEASE
  413. Diet-induced alteration of microbiota and development of obesity, nonalcoholic fatty liver disease, and diabetes: study protocol of a prospective study
  414. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice
  415. Mitochondria of mice and men: moderate magnetic fields in obesity and fatty liver
  416. PREVALENCE OF NONALCOHOLIC fatty liver DISEASE AMONG METABOLIC SYNDROME SUBJECTS & ITS RELATION WITH CENTRAL obesity: A …
  417. Ultrasonographic and biochemical evaluation of visceral obesity in obese women with non-alcoholic fatty liver disease
  418. Coadministration of epigallocatechin‐3‐gallate (EGCG) and caffeine in low dose ameliorates obesity and nonalcoholic fatty liver disease in obese rats
  419. obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice
  420. Sechium edule Shoot Extracts and Active Components Improve obesity and a fatty liver That Involved Reducing Hepatic Lipogenesis and Adipogenesis in High-Fat …
  421. Lipid-rich environment: a key role promoting carcinogenesis in obesity-related non-alcoholic fatty liver disease
  422. Endocrine status of adolescent girls with non-alcoholic fatty liver disease and obesity
  423. Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?
  424. Genetics of common obesity and nonalcoholic fatty liver disease
  425. obesity-independent association of human adenovirus Ad37 seropositivity with nonalcoholic fatty liver disease
  426. Occurrence and clinical management of nonalcoholic fatty liver disease in obesity patients: a literature review
  427. Low circulating levels of neurotensin in women with nonalcoholic fatty liver disease associated with severe obesity
  428. Laboratory predictors of the non-alcoholic fatty liver in the persons with abdominal obesity
  429. The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity
  430. Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese
  431. Association of osteoprotegerin with obesity, insulin resistance and non-alcoholic fatty liver disease in children
  432. Role of-55CT polymorphism of UCP3 gene on non alcoholic fatty liver disease and insulin resistance in patients with obesity
  433. Increased serum leukocyte cell-derived chemotaxin 2 (LECT2) levels in obesity and fatty liver
  434. Raised hepatic free fatty acids in a patient with acute fatty liver after gastric surgery for morbid obesity.
  435. Nonalcoholic fatty liver: The Association with Metabolic Abnormalities, Body Mass Index and Central obesity—A…
  436. Algorithm of diagnosis eating disorders and nutritional status in patients with nonalcoholic fatty liver disease, obesity and hypertension
  437. Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease
  438. The correlation between obesity-related diseases and non-alcoholic fatty liver disease in women in the pre-operative evaluation for bariatric surgery assessed by …
  439. fatty liver and obesity: phenotypically correlated but genetically distinct traits in a mouse model of type 2 diabetes
  440. INFLUENCE OF GASTROINTESTINAL HORMONES ON THE DEVELOPMENT OF obesity AND NON-ALCOHOLIC fatty liver DISEASE IN CHILDREN
  441. Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children …
  442. Symposium 1: Overnutrition: consequences and solutions Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome
  443. … approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity
  444. Copeptin relates to a fatty liver and measures of obesity in a South African population with mixed ethnicities
  445. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the …
  446. Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil
  447. Cholecystectomy versus central obesity or insulin resistance in relation to the risk of nonalcoholic fatty liver disease: the third US National Health and Nutrition …
  448. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
  449. Effects of green coffee extract supplementation on glycemic indexes, leptin, and obesity values in patients with non-alcoholic fatty liver disease
  450. Host genetic variants in obesity-related nonalcoholic fatty liver disease
  451. Estimated cardiorespiratory fitness attenuates the impacts of sarcopenia and obesity on non-alcoholic fatty liver in Korean adults
  452. … of New Opportunities of Pharmacological Protection at the Early Stages of a Non-Alcoholic fatty liver Disease Associated With obesity and Metabolic Syndrome
  453. Beneficial effects of Omega-3 fatty acids in nonalcoholic fatty liver disease, in child‐hood obesity
  454. The association of dehydroepiandrosterone, obesity, waist-hip ratio and insulin resistance with fatty liver in postmenopausal women–a hyperinsulinemic euglycemic …
  455. Effect of seyoeum on obesity, insulin resistance, and nonalcoholic fatty liver disease of high-fat diet-fed C57BL/6 mice
  456. Nonalcoholic fatty liver Disease in obesity and Type 2 Diabetes
  457. Clinical observation of patient with obesity and non-alcoholic fatty liver disease case study
  458. IFN-α-2b treatment protects against diet-induced obesity and alleviates non-alcoholic fatty liver disease in mice
  459. Effects of knee loading on obesity‐related non‐alcoholic fatty liver disease in an ovariectomized mouse model with high‐fat diet
  460. SCCA-IgM as a potential biomarker of non-alcoholic fatty liver disease in patients with obesity, prediabetes and diabetes undergoing sleeve gastrectomy
  461. … between a pediatric health promotion center and a pediatric obesity clinic in detecting metabolic syndrome and non-alcoholic fatty liver disease in children
  462. Two Cases Reports of Chlid fatty liver with obesity
  463. Genetic variants associated with obesity and insulin resistance in Hispanic boys with nonalcoholic fatty liver disease
  464. An assessment of bacterial overgrowth and translocation in the non-alcoholic fatty liver of patients with morbid obesity
  465. … of Grape Extract, Green Tea Extract and l‐Carnitine Improves High‐fat Diet‐induced obesity, Hyperlipidemia and Non‐alcoholic fatty liver Disease in Mice
  466. Tissue inhibitors of metalloproteinase-1 and 2 and obesity related non-alcoholic fatty liver disease: is there a relationship?
  467. Non-alcoholic fatty liver disease is associated with impairment of ejection fraction among individuals with obesity undergoing bariatric surgery: results of a cross …
  468. Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice
  469. Investigating the onset of insulin resistance and non-alcoholic fatty liver disease in obesity-induced cardiac dysfunction
  470. Evaluation of melatonin hormone and nitric oxide levels in non-alcoholic fatty liver patients in relation to obesity and oxidative stress
  471. obesity and risk of nonalcoholic fatty liver disease: a comparison of bioelectrical impedance analysis and conventionally-derived anthropometric measures
  472. A low creatinine to body weight ratio predicts the incident nonalcoholic fatty liver disease in nonelderly Chinese without obesity and dyslipidemia: a …
  473. Estrogen inhibits the effects of obesity and alcohol on mammary tumors and fatty liver
  474. Virtual reality: new insights regarding the prevalence of nonalcoholic fatty liver disease in children and adolescents with obesity using magnetic resonance imaging
  475. Improving high-fat diet-induced obesity and fatty liver by adipose tissue targeted delivery of vascular endothelial growth factor-B
  476. Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C> G) in the development of fatty liver
  477. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery
  478. A case study on a non-alcoholic fatty liver disease (NAFLD) patient improved by the oriental obesity therapy program
  479. (S) YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and …
  480. Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero
  481. Nonalcoholic fatty liver disease in Japanese patients with severe obesity who received laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) in comparison to non …
  482. Effect of TSH on Non-Alcoholic fatty liver Disease (NAFLD) independent of obesity in children of predominantly Hispanic/Latino ancestry by causal mediation …
  483. Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesity
  484. Expression and significance of fat mass and obesity associated gene and forkhead transcription factor O1 in non-alcoholic fatty liver disease
  485. Chronic intake of moderate fat-enriched diet induces fatty liver and low-grade inflammation without obesity in rabbits
  486. Impact of Childhood obesity in fatty liver Disease
  487. Therapeutic potential of interleukin-6 in preventing obesity-and alcohol-associated fatty liver transplant failure
  488. … glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a …
  489. Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice
  490. Factors Governing Development of Non-Alcoholic fatty liver Disease and Insulin Resistance in obesity
  491. Autologous subcutaneous adipose tissue transplants improve adipose tissue metabolism and reduce insulin resistance and fatty liver in diet‐induced obesity rats
  492. Impacts of long-term CPAP therapy on fatty liver in male OSA patients with abdominal obesity
  493. Protective role of pomegranate on fatty liver in obesity: an experimental chemical & histopathological study
  494. obesity and the pathogenesis of nonalcoholic fatty liver disease
  495. Insulin-like growth factor binding protein-1, non-alcoholic fatty liver disease, and its relationship with fructose consumption in children with obesity
  496. Non-alcoholic fatty liver disease associated with obesity: therapeutic opportunities
  497. Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults
  498. Non-alcoholic and alcoholic fatty liver disease in patients suffering from biliary tract pathology and obesity: clinical and functional aspects
  499. POCU1b, the n-butanol soluble fraction of polygoni cuspidati rhizoma et radix, attenuates obesity, non-alcoholic fatty liver, and insulin resistance Via …
  500. Serum γ‐glutamyl transpeptidase levels and hypertension in non‐drinkers: a possible role of fatty liver in the pathogenesis of obesity related hypertension
  501. Central obesity but not generalised obesity (body mass index) predicts high prevalence of fatty liver (NRFLD), in recently detected untreated, IGT and type 2 diabetes …
  502. Nonalcoholic fatty liver Disease in Non-Obese Subjects With Abdominal obesity is Associated With A Higher Risk of Advanced Cardiovascular Disease: A 14 Year …
  503. Ligularia fischeri and its constituent 3, 4-dicaffeoylquinic acid improve obesity-induced nonalcoholic fatty liver disease by regulating lipid metabolism and activating …
  504. Risk factors such as male sex, smoking, metabolic syndrome, obesity, and fatty liver do not justify screening colonoscopies before age 45
  505. obesity and liver disease: evaluation of fatty infiltration of the liver using ultrasonic attenuation
  506. Effect of Litchi chinensis on adipose and hepatic tissues in rats with obesity and non-alcoholic fatty liver disease (NAFLD)
  507. Furthering the understanding of maternal obesity in nonalcoholic fatty liver disease
  508. obesity AND NON-ALCOHOLIC fatty liver DISEASE: PN1-02
  509. The nutraceutical effect of Scenedesmus dimorphus for obesity and nonalcoholic fatty liver disease–linked metabolic syndrome
  510. Pilot study: asymptomatic hyperuricemia patients with obesity and nonalcoholic fatty liver disease have increased risk of double contour sign
  511. Hepatopulmonary syndrome caused by hypothalamic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma: a case report
  512. obesity-Induced Non-alcoholic fatty liver Disease (NAFLD): Role of Hyperhomocysteinemia
  513. Fat mass and obesity‐associated gene variations are related to fatty liver disease in HIV‐infected patients
  514. Role of Cyp2b in Unsaturated fatty Acid Metabolism, obesity, and Non-Alcoholic fatty liver Disease
  515. Prevalence of fatty liver and its association with indices of obesity, liver function and hyperlipidemia among adult males
  516. A Case Study on a Patient with Non-alcoholic fatty liver Disease (NAFLD) Improved on Sonography by Oriental obesity Therapy
  517. Evaluation of serum neopterin levels and its relationship with adipokines in pediatric obesity-related nonalcoholic fatty liver disease and healthy adolescents
  518. The stomach as an endocrine organ: Expression of key modulatory genes and their contribution to obesity and non-alcoholic fatty liver disease (NAFLD)
  519. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage
  520. Nonalcoholic fatty liver disease can be predicted by retinal vascular changes in patients with obesity without hypertension or diabetes
  521. Vitamin D deficiency, a noninvasive marker of steatohepatitis in patients with obesity and biopsy proven nonalcoholic fatty liver disease
  522. Nutrition: A promising route for prevention and management of obesity-related nonalcoholic fatty liver disease
  523. The association of obesity, metabolic syndrome, diabetes, and cardiovascular disease with nonalcoholic fatty liver disease.
  524. The potential prophylactic effect of orange peel administration on fatty liver and hyperlipidemia in an animal model of diet induced obesity
  525. fatty liver disease and other complications of obesity
  526. Impacts of types and degree of obesity on non-alcoholic fatty liver disease and related dyslipidemia in Chinese school-age children?
  527. … -induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The fatty liver in obesity study
  528. Hepatic free fatty acids in alcoholic liver disease and morbid obesity
  529. J NI. The Risk Factors Of Non-Alcoholic fatty liver Disease Prevalence In obesity With Or Without Diabetes Mellitus
  530. Predictive value of serum ferritin in combination with alanine aminotransferase and glucose levels for noninvasive assessment of NAFLD: fatty liver in obesity (FLiO) …
  531. Ptrf transgenic mice exhibit obesity and fatty liver
  532. Tissue changes in the development of fatty liver by chronic ingestion of sucrose associated with obesity and dyslipidemia in rats
  533. Dietary sucrose regulates the expression of the Cd36 gene in hepatic tissue of rats with obesity and Non Alcoholic fatty liver Disease (NAFLD)
  534. The Effect of the Short‐Term Growth Hormone Administration on Non‐Alcoholic fatty liver Disease in Diet‐Induced obesity Models
  535. Non-alcoholic fatty liver disease in children: a new complication of obesity
  536. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men
  537. Bitter melon powder protects against obesity-associated fatty liver disease by improving colonic microenvironment in rats with high-fat diet-induced obesity
  538. … /visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver …
  539. fatty degeneration of the liver after intestinal bypass for obesity
  540. School nutrition program; prevention of obesity and fatty liver in children
  541. Effects of MGB on obesity-Related Co-Morbidities: Lipids, Hypertension, Non-Alcoholic fatty liver, etc.
  542. Hepatocellular proliferation and hepatocarcinogen bioactivation in mice with diet-induced fatty liver and obesity
  543. Effect of obesity on nonalcoholic fatty liver disease in Chinese women with polycystic ovary syndrome
  544. Diagnosis of fatty liver complicated by simple obesity in children: serum ALT and its correlation with abdominal CT and liver biopsy
  545. fatty liver disease among other comorbidities requiring early diagnosis in pediatric obesity
  546. … metabolic syndrome and related disorders: a commentary on: translational research methods in diabetes, obesity, and nonalcoholic fatty liver disease. A focus …
  547. Gut microbiota interplay between obesity and non alcoholic fatty liver.
  548. Reduced cardio‐respiratory fitness in obesity with and without nonalcoholic fatty liver disease
  549. ADVANTAGES OF BIOCHEMICAL METHODS OF DIAGNOSING FIBROSIS IN NON-ALCOHOLIC fatty liver DISEASE IN ADOLESCENTS WITH obesity
  550. Alcoholic liver disease with nonalcoholic fatty liver disease and obesity
  551. … and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver …
  552. Abnormal liver Function Tests and Metabolic Syndrome—Is fatty liver Related to Risks for Atherosclerosis beyond obesity?
  553. … of the relationship between genetic and environmental risk factors associated with obesity and insulin resistance in South African patients with non-alcoholic fatty liver …
  554. liver fatty acid-binding protein and obesity
  555. Relationship between nonalcoholic fatty liver disease and cardiovascular disease in children with obesity
  556. A case report of adolescent nonalcoholic fatty liver disease (NAFLD) with obesity
  557. Estimating the Race/Ethnic-Specific Association Between obesity and Type 2 Diabetes, and the Role of Non-Alcoholic fatty liver Disease
  558. Macrophages and scavenger receptors in obesity‐associated non‐alcoholic liver fatty disease (NAFLD)
  559. Variations in dietary intake after bypass surgery for obesity. Possible relation to development of fatty liver after jejunoileal bypass.
  560. Prevalence of obesity, non-alcoholic fatty liver and insulin resistance and their inter relationship among type II diabetic patients attending diabetic centre …
  561. Analysis of the Correlation Between Ultrasonography Diagnosis fatty liver Grade and Hyperlipidemia and obesity Indicators by Age Groups
  562. Hepatic cirrhosis secondary to nonalcoholic fatty liver disease in a 12-year-old girl with morbid obesity
  563. Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease
  564. Ultrasound in the diagnostics of fatty liver in obesity
  565. Physical activity reduce hepatic apoptosis in patients with non-alcoholic fatty liver disease and visceral obesity
  566. liver fatty acid-binding protein may be a useful marker for non-alcoholic fatty liver disease but obesity is a major concern
  567. Family history of coronary heart disease is associated with a higher incidence of nonalcoholic fatty liver disease: Central obesity the likely link
  568. ER stress and autophagy in obesity and nonalcoholic fatty liver disease
  569. … and parameters of glucose and lipid metabolism at different clinical and morphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity
  570. Moderation effect of handgrip strength on the associations of obesity and metabolic syndrome with fatty liver in adolescents
  571. Nonalcoholic fatty liver disease and liver fibrosis in bariatric patients: Tehran obesity treatment study (TOTS)
  572. Ethnic perception of obesity in fatty liver disease
  573. Metabolic Changes Underlying Interactions Between obesity and Non‐Alcoholic fatty liver Disease in South Asian Adults
  574. obesity, non alcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD)
  575. Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation
  576. Synthesis and Biological Evaluation of 5-Benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione Derivatives for the Treatment of obesity-Related Nonalcoholic fatty liver …
  577. Effect of intermittent versus continuous exercise on obesity and fatty liver in rats fed with high-fat diet
  578. Discovery of a Potent 9‐Deazaxanthine‐based Agent for the Treatment of obesity‐Related Non‐alcoholic fatty liver Disease
  579. Hypolipidemic and anti-obesity effect of nobiletin and its role in prevention of fatty liver in high fat diet-fed rats.
  580. obesity, fatty liver and the putative role of the sympathetic nervous system: a review.
  581. … of the Humoral Component of the Immune System as a Basis for the Progression of Non-Alcoholic fatty liver Disease in Patients with obesity and Concomitant Biliary …
  582. Mechanisms linking obesity, chronic kidney disease and fatty liver disease
  583. Bariatric surgery for nonalcoholic fatty liver disease in adolescents with severe obesity
  584. Prediction of non-alcoholic fatty liver disease by obesity indices
  585. obesity-related diseases and syndromes: Insulin resistance, type 2 diabetes mellitus, non-alcoholic fatty liver disease, cardiovascular disease, and metabolic …
  586. liver transplantation in patients with non-alcoholic fatty liver disease and obesity.
  587. The waist-to-hip ratio is a better obesity index than body mass index and waist circumference for screening for nonalcoholic fatty liver disease in postmenopausal …
  588. Combined Influence of Insulin Resistance, Overweight/obesity, and fatty liver as Risk Factors for Type 2 Diabetes
  589. … OF liver TISSUE IN PATIENTS WITH fatty liver DISEASE OF NON-ALCOHOLIC AND ALCOHOLIC ORIGIN ON THE BACKGROUND OF obesity AND …
  590. The impact of P‐selectin deficiency on obesity‐associated non‐alcoholic fatty liver disease (1116.8)
  591. Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice
  592. SAT-LB015 Association of Subclinical Hypothyroidism with Nonalcoholic fatty liver in Children with Overweight and obesity
  593. Prevalence of nonalcoholic fatty liver disease in young patients with abdominal obesity and hypertension
  594. … -based Structural Equation Model Analysis of Behavioral Intention for Young and Middle-aged Patients with obesity-related Nonalcoholic fatty liver Disease in TCM …
  595. Electroacupuncture for treatment of simple obesity complicated with fatty liver
  596. Morbid obesity, non-alcoholic fatty liver disease, metabolic syndrome and bariatric surgery
  597. Beneficial effects of metformin in diet-induced obesity associated non-alcoholic fatty liver disease
  598. Non-alcoholic fatty liver Disease in obesity
  599. Role of PAI-1 in pediatric obesity and nonalcoholic fatty liver disease
  600. Pharmacological inhibition or genetic ablation of soluble epoxide hydrolase attenuates obesity‐induced nonalcoholic fatty liver disease
  601. Nonalcoholic fatty liver Disease is More Strongly Associated with Arteriosclerosis than is Abdominal obesity in Health Check-up Examinees
  602. Serum liver fatty acid binding protein levels correlate positively with obesity and insulin resistance in Chinese young adults
  603. Severe visceral obesity, fatty liver and diabetes after orchiectomy for prostate cancer
  604. Microvesicles as biomarkers in diabetes, obesity and non-alcoholic fatty liver disease: current knowledge and future directions
  605. Relationships between central obesity, fructose intake, and non-alcoholic fatty liver disease in overweight Hispanic adolescents
  606. Sympathetic Overactivity Contributes to the Pathogenesis of Non‐alcoholic fatty liver Disease During Diet‐induced obesity
  607. The impacts of obesity and metabolic abnormality on carotid intima-media thickness and non-alcoholic fatty liver disease in children from an inland Chinese …
  608. Associations between overweight and obesity and risk factors for cardiovascular disease and fatty liver in young offenders serving community orders
  609. The Intestinal Gut Microbiome as a Biomarker and Driver of obesity and Non-alcoholic fatty liver Disease
  610. Childhood obesity related to development of fatty liver in children from 6 to 14 in Cochabamba, Bolivia
  611. Correction: Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural …
  612. … vaspin level as a predictive indicator in the amelioration of fatty liver and metabolic disturbance in patients with severe obesity after laparoscopic vertical …
  613. obesity, Inflammation, Nonalcoholic fatty liver Disease, and Hepatocellular Carcinoma
  614. Increased Prevalence of obesity and Metabolic Syndrome in Patients With Alcoholic fatty liver Disease: 837
  615. Oxidative stress assessment in different ethnic groups of girls with exogenous constitutional obesity complicated by non-alcoholic fatty liver disease
  616. Partially hydrogenated vegetable oil containing 5% trans fats when combined with fructose exacerbates obesity and non-alcoholic fatty liver disease in rats
  617. obesity DEPENDENT METABOLIC SIGNATURES ASSOCIATED WITH NONALCOHOLIC fatty liver DISEASE PROGRESSION: 1304
  618. Nonalcoholic fatty liver disease in patients with morbid obesity Niealkoholowa stłuszczeniowa choroba wątroby w otyłości olbrzymiej
  619. … Effect of Brown Rice on Superoxide Dismutase Level and Non-alcoholic fatty liver in an Sprague–Dawley Rat Model of High-fat High-fructose Diet-induced obesity
  620. The role of vitamin D3 in high fat diet induced fatty liver disease and obesity
  621. Research progress of stearoyl-CoA desaturase-1 on obesity and non-alcoholic fatty liver disease Abstract
  622. … obesity: brothers-in-arms: Comment on: PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver …
  623. Study on the interaction between matrix metalloproteinases gene polymorphism and central obesity in nonalcoholic fatty liver disease
  624. Animal Models of obesity Characterized by Non-alcoholic fatty liver Disease (NAFLD)
  625. Wheat bran with unbound ferulic acid does not alter obesity, insulin resistance or fatty liver in obese rats compared to wheat bran with bound ferulic acid (829.22)
  626. Role of leptin and leptin resistance in non-alcoholic fatty liver disease development in persons with obesity and overweight
  627. Prevention of obesity-induced nonalcoholic fatty liver disease using grape pomace extract.
  628. Non-alcoholic fatty liver youth with obesity
  629. obesity and non-alcoholic fatty liver-therapies in ayurvedic medicines
  630. obesity and non-alcoholic fatty liver disease
  631. The clinical features of the non-alcoholic fatty liver disease with chronic kidney disease (chronic pyelonephritis) and obesity
  632. The effects of mechanical loading on high-fat induced obesity and non-alcoholic fatty liver disease
  633. Metabolomics reveals that alterations in circulating a-ketoglutarate may be relevant in the assessment of morbid obesity-associated nonalcoholic fatty liver disease
  634. … spectroscopy (1H-MRS)-based neurometabolite levels and cognitive function in relation to visceral obesity and non-alcoholic fatty liver disease (P14-019-19)
  635. Neurotensin and nonalcoholic fatty liver disease: beyond obesity
  636. Study on the correlation of fibroblast growth factor 21 level with the obesity, lipid metabolism and insulin resistance in patients with non-alcoholic fatty liver …
  637. Maternal obesity Programs Offspring’s Predisposition to Non‐Alcoholic fatty liver Disease and Steatohepatitis
  638. … from green banana (Musa sp.) attenuates non-alcoholic fat liver accumulation and increases short-chain fatty acids production in high-fat diet-induced obesity …
  639. … bacterial overgrowth and microbial translocation products in peripheral blood samples and its relationship with nonalcoholic fatty liver disease, in morbid obesity …
  640. liver electrical impedance tomography for early identification of fatty infiltrate in obesity
  641. Regulation of obesity and Non-alcoholic fatty liver Diseases by Modulation of the Gut Microbiota Through Inflammasome: its Mechanism and Potential for Clinical …
  642. … American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver …
  643. … MELLITUS IN VARIOUS CLINICAL AND MORPHOLOGICAL FORMS OF NONALCOHOLIC fatty liver DISEASE IN PATIENTS WITH ABDOMINAL obesity
  644. fatty liver and obesity: phenotypically
  645. Interleukin-15 in the Regulation of obesity and fatty liver Disease
  646. Correlation between plasma fibroblast growth factor 21 level, obesity and insulin resistance in nonalcoholic fatty liver disease patients.
  647. S1189 Incorporation of obesity Medicine Into the Care of Patients With Nonalcoholic fatty liver Disease: 1-Year Interim Results
  648. Aroclor 1260 Exposure Worsens Hepatic And Systemic Inflammation In An Animal Model Of Diet-Induced obesity And Nonalcoholic fatty liver Disease: 682
  649. Role of fatty liver Disease in Childhood obesity
  650. Diabetes Mellitus, obesity and Underlying Non Alcoholic fatty liver Disease-Independent Risk Factors for Hepatocellular Carcinoma
  651. Ultrasound in the diagnostics of fatty liver in obesity
  652. Increased placental fatty acid transporter 6 and binding protein 3 expression and fetal liver lipid accumulation in a mouse model of obesity in pregnancy
  653. … INDEX (AHI) PREDICTS NON-ALCOHOLIC fatty liver DISEASE (NAFLD) ACTIVITY SCORE (NAS) IN A COHORT OF PATIENTS WITH MORBID obesity …
  654. Ultrasound grading of fatty liver and association with obesity
  655. The Analysis of The efficacy and risk factors in obesity with non-alcoholic fatty liver disease subjects treated with orlistat.
  656. obesity and Pediatric fatty liver: The Silent Epidemic and Significant Health Problem
  657. The Influence of Alcohol Consumption on the Association between obesity and fatty liver: 1515
  658. An epidemiological study of obesity and fatty liver of students in Japan
  659. Relationships between Parameters of Insulin Sensitivity, obesity and liver Aminotransferases in Patients with Nonalcoholic fatty liver Disease
  660. P1070 FAILURE TO DIAGNOSE obesity AND SCREEN FOR fatty liver DISEASE IN PEDIATRIC PRACTICE
  661. liver function in patients with coronary artery disease and nonalcoholic fatty liver disease associated with obesity
  662. … exercise on serum level of retinol-bonded protein 4, abdominal obesity, and metabolic markers in postmenopausal women with non-alcoholic fatty liver
  663. Induction method of non-alcoholic fatty liver model in obesity and obesity-resistant rats.
  664. Identifying Non-Alcoholic fatty liver Disease on Ultrasound and its Correlation with obesity
  665. 3D Co-Registration of MRI and Histology in a Mouse Model of obesity and Non-Alcoholic fatty liver Disease
  666. TNFα-INDUCED PHOSPHORYLATION OF C/EBPβ-SERINE-239 IS CRITICAL FOR THE DEVELOPMENT OF obesity AND fatty liver: 63
  667. HIGH FRUCTOSE FEEDING INDUCES COPPER DEFICIENCY: A NOVEL MECHANISM FOR obesity RELATED fatty liver: 1543
  668. High dietary fat exacerbates weight gain and obesity in female liver fatty acid binding protein gene-ablated mice
  669. A comparative study of diet-induced obesity and diet-induced obesity-resistant non-alcoholic fatty liver in rats.
  670. Visceral obesity as atherogenesis predictor in patients with nonalcoholic fatty liver disease
  671. Non-alcoholic fatty liver disease: an emerging problem with childhood obesity
  672. IκB kinase ε: A potential therapeutic target for obesity (and nonalcoholic fatty liver disease)?
  673. Comorbidities: Non Alcoholic fatty liver in Childhood obesity
  674. Relationship between insulin resistance, incidence of fatty liver and serum ferritin level in adults with simple obesity
  675. Statins, diabetes, obesity, nonalcoholic fatty liver disease, and hepatocellular carcinoma
  676. A Role for Recruited Myeloid Cells in obesity Induced fatty liver Disease
  677. A comparative study of diet-induced obesity and diet-induced obesity-resistant non-alcoholic fatty liver in rats.
  678. Physical Activity in Nonalcoholic fatty liver Disease in terms of Visceral obesity: 1514
  679. Intestinal Microbiota-obesity–fatty liver
  680. Abstract P380: obesity and Non-Alcoholic fatty liver Disease in Children
  681. Nonalcoholic fatty liver diseases as dramatic consequence of obesity
  682. obesity and insulin resistance in patients with non-alcoholic fatty liver disease diagnosed by non invasive diagnostic methods
  683. Non-alcoholic fatty liver disease in a young patient with obesity, hyperandrogenism, postcholecystectomy syndrome and reactive pancreatitis. A clinical case
  684. … characteristics of the T-and B-cell immunity, depending on the body mass index in the patients with the nonalcoholic fatty liver disease in combination with the obesity
  685. Central obesity and non-alcoholic fatty liver disease in people living with HIV: a case for targeted
  686. Polyphenol-rich foods as interventions for obesity and fatty liver disease
  687. fatty acid synthase (FASN) inhibitors as potential treatment for cancer, obesity, and liver related disorders
  688. Dietary iron overload induces visceral adipose tissue insulin resistance and hyper-resistinemia, and synergizes with obesity and fatty liver in inducing systemic insulin …
  689. CD8+ T CELLS REGULATE liver INJURY IN obesity‐RELATED NONALCOHOLIC fatty liver DISEASE
  690. Research Article Compound C Protects Mice from HFD-Induced obesity and Nonalcoholic fatty liver Disease
  691. ALGORITHM OF DIAGNOSIS EATING DISORDERS AND NUTRITIONAL STATUS IN PATIENTS WITH NONALCOHOLIC fatty liver DISEASE, obesity …
  692. Nutritional programming by maternal obesity: insights into the development of non‐alcoholic fatty liver disease
  693. Prevalence and associated risk factors for obesity and nonalcoholic fatty liver disease in adolescents in Xi’an, Shaanxi province, China.
  694. Developmental Programming of obesity and fatty liver Disease in Offspring Exposed to Maternal obesity and Dietary Intervention
  695. Relationship between nonalcoholic fatty liver disease and obesity
  696. Prediction of course and progression of nonalcoholic fatty liver disease in patients with obesity and pathology of the biliary tract with the help of mathematical modeling …
  697. … OF CARBOHYDRATE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES IN NONALCOHOLIC fatty liver DISEASE AND obesity (Literature review and own …
  698. Burden of obesity and Nonalcoholic fatty liver Disease in Helicobacter Infected Pakistani Population
  699. Causal mediation analysis of Subclinical Hypothyroidism in children with obesity and Non-Alcoholic fatty liver Disease
  700. Elucidating the mechanism by which the antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease
  701. The usefulness of methacetin breath test in the initial diagnosis of nonalc oholic fatty liver disease in children with simple obesity-preliminary report.
  702. … , a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver …
  703. Aerobic exercises versus low-caloric diet for mild fatty liver patients with central obesity
  704. Interleukin 15 in nonalcoholic fatty liver disease and obesity
  705. Effectiveness of taurine and oyster on prevention and treatment of hyperlipidemia and fatty liver with obesity in rats chronically fed with high fat diet
  706. Association between neck circumference and non-alcoholic fatty liver disease in children and adolescents with obesity
  707. Success Rate of liver Stiffness Measurement Using Transient Elastography in Non-alcoholic fatty liver Disease Patients with obesity and Its Influencing Factors
  708. Effect of high sucrose diet on apolipoprotein gene expression in fatty liver with obesity
  709. ECTOPIC ADIPOSITY OF NON-ALCOHOLIC fatty liver DISEASE IS A STRONG DETERMINANT OF POOR BONE HEALTH IN obesity
  710. Influencing factor of fatty liver in simple obesity children
  711. fatty liver, obesity AND HEPATOCELLULAR CANCER: IMPACTS OF UNCOUPLING PROTEIN-2 AND FLUVASTATIN
  712. Non-alcoholic fatty liver disease (NAFLD) in relation to insulin resistance, metabolic syndrome and obesity.
  713. Waist circumference triglyceride index (WTI) is useful to predict non-alcoholic fatty liver disease in childhood obesity.
  714. The state of lipid, carbohydrate metabolism and function of cardiovascular system of patients with non-alcoholic fatty liver disease, overweight and obesity
  715. DIET INDUCED obesity ALTERS PHASE II HEPATIC XENOBIOTIC METABOLISM: IMPLICATIONS FOR NONALCOHOLIC fatty liver DISEASE: 1915
  716. The role of MDM2 in the pathogenesis of obesity-induced non-alcoholic fatty liver disease
  717. Histology of Non-Alcohol fatty liver Disease Among Subjects with Medically Complicated obesity: Does Gender Play a Role?: 514
  718. Diet‐induced obesity and non‐alcoholic fatty liver disease in TRPV1 null mice
  719. Ionic Detoxification Reduces obesity and fatty liver in Rats Fed a High-Fat Diet
  720. Central obesity but not generalised obesity (body mass index) predicts high prevalence of fatty liver (NAFlD), in recently detected untreated, IGT and type 2 …
  721. obesity is not associated with non-alcoholic fatty liver disease (NAFLD) in HIV-positive gay males
  722. Dietary Cocoa (Theobroma Cacao) Supplementation Improves obesity-related fatty liver Disease in Mice
  723. Association between obesity Measures, Inflammatory, Oxidative Stress and Neuronal Injury Markers in Obese Women with Non-Alcoholic fatty liver
  724. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics
  725. Hyperexpression of N-acetylglucosaminyltransferase-III in liver tissues of transgenic mice causes fatty body and obesity through severe accumulation of Apo AI and …
  726. Alcohol intake is less important as predictive factors for development of fatty liver disease compared to obesity, impairment of glucose metabolism and dyslipidemia …
  727. Hepatoprotection of Vitamin E and Green Tea on Oxidative Stress and Inflammatory Responses In Animal Models of obesity-Triggered Nonalcoholic fatty liver …
  728. liver specific depletion of mitochondrial ATP transporter enhances uncoupled respiration and prevents fatty liver and obesity
  729. Human Maternal obesity in the Development of Nonalcoholic fatty liver Disease in a Germ-free Mouse Model: Identifying the Role of the Infant Gut …
  730. obesity and Non-Alcoholic fatty liver Disease: Cause and Effect?
  731. OP06 Maternal obesity programs offspring innate immune dysregulation in non-alcoholic fatty liver disease
  732. liver fatty acid binding protein (L-FABP) as a target for the prevention of high fat diet induced obesity and hepatic steatosis
  733. High g-glutamyl-transferase fractions as new markers to identify non-alcoholic fatty liver disease in childhood obesity
  734. Study of hepatic leptin and insulin signaling during nonalcoholic fatty liver disease (NAFLD) progression in morbid obesity: 654
  735. Soy ß-conglycinin improves obesity-induced metabolic abnormalities in a rat model of nonalcoholic fatty liver
  736. … effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver axis crosstalk in an” in vivo” model of early obesity and non-alcoholic fatty liver …
  737. Correlation among fatty liver, obesity and dyslipidemia in staff of government division.
  738. 1056 Incorporation of obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale fatty liver Disease Model
  739. … OF DETOXIFYING FUNCTION OF THE liver IN PATIENTS WITH HYPERTENSION AND obesity COMBINED WITH NON-ALCOHOLIC fatty liver …
  740. The intensity of lipid distress syndrome in patients with non-alcoholic fatty liver disease on the background of obesity and chronic kidney disease (chronic …
  741. Role of the orphan nuclear receptors TR2 and TR4 in the pathophysiology of obesity and non-alcoholic fatty liver disease
  742. CPAP in fatty liver with obesity without topiramate and MOVE program does not cause sustained weight loss but may results in weight gain-an opinion
  743. Impact of Maternal obesity on Offspring Bile Acid Homeostasis and Pathologic Progression in Non‐Alcoholic fatty liver Disease
  744. Metabolism of cyclic GMP in non-alcoholic fatty liver disease in morbid obesity
  745. … DAMAGE IN PATIENTS WITH NON-ALCOHOLIC fatty liver DISEASE COMBINED WITH METABOLIC SYNDROME DEPENDING ON THE obesity …
  746. Diagnosis and treatment strategies for fatty liver when obesity coexists with alcohol consumption
  747. … 5 (Joint Nutrition Society and BAPEN Symposium): Too many pies: metabolic competencies in obesity The importance of fatty liver disease in clinical practice
  748. obesity and insulin resistance in nonalcoholic fatty liver
  749. Impact of obesity, Metabolic Syndrome, and Nonalcoholic fatty liver Disease on Systemic Inflammation and Subclinical Atherosclerosis: The Multi-Ethnic Study of …
  750. Hypolipidemic and anti-obesity effect of nobiletin and its role in prevention of fatty liver in high fat diet-fed rats.
  751. Maternal obesity promotes offspring non-alcoholic fatty liver disease (NAFLD) through disruption of endoplasmic reticulum homeostasis: 49
  752. Alcoholic liver disease with nonalcoholic fatty liver disease and obesity.
  753. PWE-112 Maternal obesity Promotes Offspring Non-Alcoholic fatty liver Disease (Nafld) Through Disruption of Endoplasmic Reticulum Homeostasis
  754. Relationship between fatty liver and Blood Lipids in Children with Simple obesity
  755. The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity
  756. … of Cell Death-Inducing DFF45-Like Effector (CIDE) Family of Proteins in Patients with obesity Associated Non-Alcoholic fatty liver Disease (NAFLD): 1163
  757. Oxidative stress and altered lipid homeostasis in the programming of offspring fatty liver 1 by maternal obesity 2
  758. Dual Therapy With Mitochondrial and Cytosolic Antioxidants Improve Non Alcoholic fatty liver Disease (NAFLD) in Diet Induced obesity (DIO) Mouse Model
  759. Correlation of obesity and Other Factors with Presence of Extra Hepatic Disease among the Patients Presenting with fatty liver
  760. liver fatty acid composition correlates with body fat and sex in a multigenic mouse model of obesity
  761. … CARBOHYDRATE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES INNONALCOHOLIC fatty liver DISEASE AND obesity (Literature review and own …
  762. Expression and significance of fat mass and obesity associated gene and forkhead transcription factor O1 in non-alcoholic fatty liver disease.
  763. Association of 24 h Behavior Rhythm with Non-Alcoholic fatty liver Disease among American Adults with Overweight/obesity
  764. Research Article Abdominal obesity as a Predictive Factor of Nonalcoholic fatty liver Disease Assessed by Ultrasonography and Transient Elastography in …
  765. … fatty liver Disease Differentiates Subpopulations with Higher Risk of Incident Type 2 Diabetes Regardless of Their Metabolic Health and obesity Status: A Nationwide …
  766. Association of single nucleotide polymorphisms in TNFA, PNPLA3, ADIPOQ and APOC3 genes with obesity and non-alcoholic fatty liver disease in north Indian …
  767. Non-alcoholic fatty liver disease and childhood obesity.
  768. Dietary fat and cholesterol in the pathogenesis of obesity and non-alcoholic fatty liver disease
  769. fatty liver of obesity—An inflammatory disease?
  770. 1857-P: Modified Mesenchymal Stromal Cells: A Novel and Safe Therapy for Treating Nonalcoholic fatty liver Disease (NAFLD) in obesity and Diabetes
  771. The impact of severe obstructive sleep apnea and obesity on nonalcoholic fatty liver disease
  772. Resveratrol stimulation of SIRT1 & exogenous delivery of FGF21 mimics metformin’s ability to alleviate non-alcoholic fatty liver disease caused by diet-induced obesity
  773. Maternal obesity Promotes Offspring Non-Alcoholic fatty liver Disease (NAFLD) through Disruption of Molecular Circadian Rhythms: 250
  774. obesity, liver steatosis, and omega-3 fatty acids
  775. The association of atherosclerosis and combination of fatty liver, insulin resistance and obesity
  776. … APNEA INFLUENCE THE HISTOLOGY OF NON ALCOHOLIC fatty liver DISEASE IN A COHORT OF PATIENTS WITH MEDICALLY COMPLICATED obesity …
  777. … of PPAR-g 2 (rs1801282) and ACE (rs4646994) genes on the onset of non-alcoholic fatty liver disease in patients with essential arterial hypertension and obesity
  778. Prevalence of non alcoholic fatty liver disease in women with morbid obesity
  779. PILOT STUDY fatty liver AND obesity: MR FAT QUANTIFICATION AND MR ELASTOGRAPHY DURING A VERY LOW-CALORIE-KETOGENIC DIET …
  780. Hepatic PUFA content impacts fatty liver in mouse models of obesity & diabetes
  781. … IN THE DEVELOPMENT AND PROGRESSION OF NON-ALCOHOL fatty liver DISEASE AND CHRONIC KIDNEY DISEASE IN PATIENTS WITH obesity
  782. … . Prevalence of fatty liver and cardiometabolic complications in overweight Indian adolescents: A brief report 11. Patient Information Page on Childhood obesity …
  783. … in Microrna-155 Leads to Reduced Atherosclerosis, Increased obesity and Nonalcoholic fatty liver Disease–A Novel Mouse Model of Metabolically Healthy obesity
  784. Nonalcoholic fatty liver disease vs. obesity on the risk of erosive oesophagitis.
  785. … Therapy with Atorvastatin and Ursodeoxycholic Acid on the Course of Ischemic Heart Disease with Co-Existent Non-Alcoholic fatty liver Disease and obesity
  786. Ethnic aspects of lipid peroxidation processes in teenagers with obesity and non-alcoholic fatty liver disease
  787. A comparative study of patients with obesity and non-alcoholic fatty liver disease, fatty liver disease with moderate and severe alcohol intake
  788. Screening for non-alcoholic fatty liver disease in the obesity epidemic.
  789. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.
  790. Clinical pharmacology of obesity and non-alcoholic fatty liver disease: GRADE evaluation of existing clinical evidence
  791. Symptoms Experience in Persons with obesity-Related Nonalcoholic fatty liver Disease
  792. Relation of Anthropometric obesity and Computed Tomography Measured Nonalcoholic fatty liver Disease
  793. fatty liver Disease in Morbidly Obese Patients in Correlation to obesity Related Co-Morbidities
  794. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease.
  795. The Thrombin Inhibitor Dabigatran Inhibits High Fat Diet-induced obesity and fatty liver Disease in Mice
  796. … EFFECT OF MILD BILIRUBIN ELEVATION IS MASKED BY THE CONFOUNDING FACTOR OF fatty liver AND ABDOMINAL obesity IN THE APPARENTLY …
  797. … Superfamily Member 1 (Them1) Suppresses Thermogenesis and Contributes to Diet-Induced obesity and Non-Alcoholic fatty liver Disease (NAFLD): 1115
  798. Impacts of obesity on metabolic profiles in patients with non-alcoholic fatty liver disease.
  799. Contributions of fatty acid and sterol synthesis to triglyceride and cholesterol secretion by the perfused rat liver in genetic hyperlipemia and obesity.
  800. Association Between Nonalcoholic fatty liver, Markers of obesity, and Serum Leptin Level in Young Adults
  801. Higher association of non-alcoholic fatty liver disease with coronary artery calcification than abdominal obesity
  802. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease.
  803. Prevalence of fatty liver in Japanese children ages 4 to 12 years old: Relationship to obesity. An epidemiological ultrasonographic survey.
  804. The genetic background modifies the effects of the obesity mutation,’fatty‘, on apolipoprotein gene regulation in rat liver
  805. Biochemical Predictors of Early Onset Non-Alcoholic fatty liver Disease in Young Children with obesity
  806. Long-term adaptation of global transcription and metabolism during induction of obesity and fatty liver in mice
  807. Changes and significance of serum visfatin levels in obesity and nonalcoholic fatty liver disease.
  808. Valproic acid obesity and non-alcoholic fatty liver disease in
  809. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes.
  810. Cardiometabolic risk factors in different clinicomorphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity
  811. Analysis of risk factors in non-alcoholic fatty liver disease in obesity-related hypertension patients.
  812. Effects of two personalized and hypocaloric dietary interventions in subjects with non-alcoholic fatty liver disease and overweight/obesity after 6 months of follow-up
  813. Lean-non alcoholic fatty liver disease (NAFLD) with central visceral obesity identifies patients with more severe disease
  814. Prevalence of liver function abnormalities and predictive markers in Chinese diabetic obesity with nonalcoholic fatty liver diseases undergoing bariatric surgery
  815. Ptrf transgenic mice exhibit obesity and fatty liver.
  816. Incidence of obesity in School Children in Rural and Urban Areas in Hokkaido, With a Report of Cases of fatty liver in Obese Children
  817. obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study.
  818. Nonalcoholic fatty liver Disease Is Associated with Type 2 Diabetes Mellitus Only in Individuals with Visceral obesity
  819. Expression of obesity-related gene and forkhead transcription factors in liver of nonalcoholic fatty liver disease rat model
  820. DEVELOPMENT OF AN ANTI-AP2 MONOCLONAL ANTIBODY TO TREAT obesity RELATED DIABETES AND fatty liver DISEASE
  821. Association of Serum Adiponectin and Metabolic Syndrome in Children with obesity and Nonalcoholic fatty liver Disease
  822. Rising obesity rates boosting liver disease risk: the typical patient with nonalcoholic fatty liver disease has a BMI above 30 and insulin resistance.
  823. Comparison of abdominal obesity and fatty liver and their association with insulin resistance and metabolic syndrome in Chinese adults.
  824. Effects of mogrosides on high-fat-diet-induced obesity and nonalcoholic fatty liver disease in mice.
  825. Inducible nitric oxide distribution in the fatty liver of a mouse with high fat diet-induced obesity.
  826. Expression of obesity-related gene and forkhead transcription factors in liver of nonalcoholic fatty liver disease rat model.
  827. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic obesity Study.
  828. … OF INSULIN RESISTANCE ON THE DEVELOPMENT OF NON-ALCOHOLIC fatty liver DISEASE AND ARTERIAL HYPERTENSION IN PATIENTS WITH obesity
  829. Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia.
  830. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans.
  831. Effect of Seyoeum on obesity, insulin resistance, and nonalcoholic fatty liver disease of high-fat diet-fed C57BL/6 mice.
  832. Transcriptome analysis of anti-fatty liver action by Campari tomato using a zebrafish diet-induced obesity model
  833. Relationship between the plasma resistin, obesity and insulin resistance in nonalcoholic fatty liver disease patients
  834. The lemon balm extract ALS-L1023 inhibits obesity and nonalcoholic fatty liver disease in female ovariectomized mice.
  835. Cutoff points of abdominal obesity indices in screening for non-alcoholic fatty liver disease in Asians.
  836. obesity and incidence of diabetes: effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver.
  837. Intracellular role of exchangeable apolipoproteins in energy homeostasis, obesity and non-alcoholic fatty liver disease.
  838. Ionic Detoxification Reduces obesity and fatty liver in Rats Fed a High-Fat Diet
  839. Lactobacillus acidophilus NS1 attenuates diet-induced obesity and fatty liver.
  840. Is the gut the key to obesity?: the involvement of the intestine in obesity, type 2 diabetes mellitus and fatty liver disease in man.
  841. Beneficial effects of phosphatidylcholine on high-fat diet-induced obesity, hyperlipidemia and fatty liver in mice.
  842. Protective Efficacy of Caralluma diffusa Methanolic Crude Extract against High-fat Diet (HFD) Induced fatty liver obesity in Albino Wistar Rat
  843. Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease.
  844. Calcium channel blockers to ameliorate obesity-associated glucose intolerance and fatty liver pathologies
  845. Serum vitamin D levels are inversely related with non-alcoholic fatty liver disease independent of visceral obesity in Chinese postmenopausal women.
  846. Differences of lifestyle behaviors between non-obese and obese non-alcoholic fatty liver disease; beyond visceral obesity and metabolic syndrome
  847. liver dysfunction following small-bowel bypass for obesity: nonoperative treatment of fatty metamorphosis with parenteral hyperalimentation
  848. A genomic and proteomic study of obesity-related non-alcoholic fatty liver disease (NAFLD)
  849. MATERNAL obesity PROGRAMS OFFSPRING INNATE IMMUNE DYSREGULATION IN NON-ALCOHOLIC fatty liver DISEASE: 1667
  850. Risk factors such as male sex, smoking, metabolic syndrome, obesity, and fatty liver do not justify screening colonoscopies before age 45.
  851. Sex hormone-binding globulin is more than a sex steroid carrier: a New therapeutic target against obesity and non-alcoholic fatty liver disease
  852. THE ASSOCIATION OF ANTHROPOMETRIC obesity MEASURES WITH CT-MEASURED NON-ALCOHOLIC fatty liver DISEASE IN THE MULTI-ETHNIC …
  853. Discovery of a potent 9-deazaxanthine-based agent for the treatment of obesity-related non-alcoholic fatty liver disease.
  854. Clinical and biochemical characteristics in type 2 diabetes mellitus with visceral obesity and nonalcoholic fatty liver disease
  855. Treatment of non-alcoholic fatty liver disease: an interpretation of the European clinical guidelines for obesity, type 2 diabetes, and digestive disease
  856. Hypothalamic orexin prevents obesity and non-alcoholic fatty liver disease in mice fed high fat diet
  857. Beneficial effects of red yeast rice on high-fat diet-induced obesity, hyperlipidemia, and fatty liver in mice.
  858. Soya protein β-conglycinin ameliorates fatty liver and obesity in diet-induced obese mice through the down-regulation of PPARγ.
  859. fatty liver, REGIONAL obesity AND TYPE 2 DIABETES MELLITUS
  860. Obeticholic Acid Ameliorates Non-Alcoholic fatty liver Disease by Improving Metabolic Profile in Dietary obesity, but Not in Obese, Diabetic FOZ/FOZ Mice
  861. Sechium edule shoot extracts and active components improve obesity and a fatty liver that involved reducing hepatic lipogenesis and adipogenesis in high-fat-diet …
  862. A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice.
  863. … of high-fat diet-induced obesity by a mixture of red grape extract, soy isoflavone and l-carnitine: implications in cardiovascular and non-alcoholic fatty liver diseases.
  864. fatty acid composition of liver and adipose tissue lipids in Wistar rats with fat diet‐induced obesity
  865. Mechanisms of non-alcoholic fatty liver disease development in patients with arterial hypertension and obesity depending on genetic predictors
  866. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.
  867. State of platelet-vessel hemostasis in patients with hypertension, abdominal obesity and nonalcoholic fatty liver disease
  868. INTERLEUKIN 15 IN PATHOGENESIS OF NON-ALCOHOLIC fatty liver DISEASE IN PATIENTS WITH obesity
  869. obesity-associated steatotic liver exhibits aberrant or altered sphingolipid composition and preferentially accumulates ceramide species containing long chain …
  870. … CHARACTERISTICS OF CYTOKINE REGULATION AND COOPERATION IN NONALCOHOLIC fatty DISEASE OF THE liver WITH UNDERLYING obesity
  871. Effects of Maresin 1, an omega-3 fatty acid-derived lipid mediator, on adipose tissue and liver function in obesity
  872. Specific modulation of hepatic estrogen receptor alpha prevents fatty liver but also obesity and insulin resistance induced by a high fat diet in mice
  873. Background pathological data in high-fat diet induced obesity mouse and relation to non-alcoholic fatty liver disease
  874. … acid desaturase indices in rats: Associations between plasma, liver and adipose tissue lipid fractions and the effects of a high-fat diet and diet-induced obesity
  875. Hyperexpression of N-acetylglucosaminyltransferase-III in liver tissues of transgenic mice causes fatty body and obesity through severe accumulation of Apo AI and …
  876. … and mitochondrial glycerol-3-phosphate dehydrogenase in the liver is linked to enhanced fatty acid oxidation in Lou/C, a rat strain resistant to obesity
  877. Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation.
  878. Studies on the relationship between obesity, and the metabolic abnormalities of carbohydrate and free fatty acids in patients with liver cirrhosis.
  879. … GEOMETRY AND MORTALITY PREDICTION BY DIFFERENT INDEXATION METHODS FOR LEFT VENTRICULAR MASS BY obesity STATUS IN 47,865 …
  880. Non-alcoholic fatty liver disease and childhood obesity
  881. Management of obesity and nonalcoholic fatty liver disease: a literature review
  882. Relationship between obesity related indicators and non-alcoholic fatty liver disease in children: a systematic review and meta-analysis
  883. Impact of obesity in Non-Alcoholic fatty liver Disease
  884. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity
  885. Nonalcoholic fatty liver disease and obesity: an obesity medicine association (OMA) clinical practice statement (CPS) 2022
  886. Effects of obstructive sleep apnea on non-alcoholic fatty liver disease in patients with obesity: a systematic review
  887. Anti-obesity medications for the management of nonalcoholic fatty liver disease
  888. Nonalcoholic fatty liver disease in children with obesity: narrative review and research gaps
  889. Impact of obesity on liver function tests: is nonalcoholic fatty liver disease the only player? A review article
  890. Does the mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? a …
  891. Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease
  892. fatty liver Disease in Patients with Prediabetes and Overweight or obesity
  893. Non-alcoholic fatty liver disease: relation to juvenile obesity, lipid profile, and hepatic enzymes
  894. obesity and nonalcoholic fatty liver disease
  895. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease
  896. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques
  897. Comparison of obesity-related indices for identifying nonalcoholic fatty liver disease: a population-based cross-sectional study in China
  898. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease
  899. Association between metabolically healthy obesity and non-alcoholic fatty liver disease
  900. obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease
  901. Association between Mediterranean Diet and fatty liver in Women with Overweight and obesity
  902. Nonalcoholic fatty liver disease in children with obesity–observations from one clinical centre in the Western Pomerania region
  903. The impact of vitamin D in non-alcoholic fatty liver disease: a cross-sectional study in patients with morbid obesity
  904. Quality of life and coping in nonalcoholic fatty liver disease: Influence of diabetes and obesity
  905. Dietary fiber‐derived short‐chain fatty acids: A potential therapeutic target to alleviate obesity‐related nonalcoholic fatty liver disease
  906. Depression and increased risk of non-alcoholic fatty liver disease in individuals with obesity
  907. Clinical Classification of obesity and Implications for Metabolic Dysfunction-Associated fatty liver Disease and Treatment
  908. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
  909. Associations between abdominal obesity indices and nonalcoholic fatty liver disease: Chinese visceral adiposity index
  910. The use of very low‐calorie diets in subjects with obesity complicated with nonalcoholic fatty liver disease: A scoping review
  911. Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity
  912. The potential of Lamiaceae herbs for mitigation of overweight, obesity, and fatty liver: studies and perspectives
  913. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review
  914. Correlation between anthropometric measurements and non-alcoholic fatty liver disease in individuals with obesity undergoing bariatric surgery: cross-sectional study
  915. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome
  916. Gender differences in the relationships among metabolic syndrome and various obesity-related indices with nonalcoholic fatty liver disease in a Taiwanese …
  917. Body composition, phenotype and central obesity indices in Egyptian women with non-alcoholic fatty liver disease
  918. Hepatocyte mitochondrial dynamics and bioenergetics in obesity-related non-alcoholic fatty liver disease
  919. Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study
  920. Metabolically healthy obesity and risk of non‐alcoholic fatty liver disease severity independent of visceral fat
  921. Assessment of lifestyle factors helps to identify liver fibrosis due to non-alcoholic fatty liver disease in obesity
  922. Sarcopenic obesity in Non-Alcoholic fatty liver Disease—The Union of Two Culprits
  923. Hypertension and histopathology severity of non-alcoholic fatty liver disease among adults with obesity: a cross-sectional study
  924. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the liver (AISF), the Italian Society of …
  925. Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver
  926. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease
  927. Review of paediatric obesity and non‐alcoholic fatty liver disease—A focus on emerging non‐pharmacologic treatment strategies
  928. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease
  929. Increased asprosin is associated with non-alcoholic fatty liver disease in children with obesity
  930. Nonalcoholic fatty liver disease and obesity
  931. Mitochondrial transplantation: opportunities and challenges in the treatment of obesity, diabetes, and nonalcoholic fatty liver disease
  932. Serum concentration of fatty acids in children with obesity and nonalcoholic fatty liver disease
  933. What do we know about nutrient-based strategies targeting molecular mechanisms associated with obesity-related fatty liver disease?
  934. Loss of TRIM67 attenuates the progress of obesity-induced non-alcoholic fatty liver disease
  935. Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: Insights from the general population
  936. Uric acid versus metabolic syndrome as markers of fatty liver disease in young people with overweight/obesity
  937. Microvesicular steatosis in individuals with obesity: a histological marker of non-alcoholic fatty liver disease severity
  938. Prevalence and clinical significance of autoantibodies in children with overweight and obesity with nonalcoholic fatty liver disease
  939. Associations among adipose tissue immunology, inflammation, exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease
  940. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
  941. Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: evidence from mediation analysis
  942. Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity
  943. Risk and protective factors of non‐alcoholic fatty liver disease in paediatric obesity: A nationwide nested case–control study
  944. Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease
  945. Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study
  946. Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases
  947. Development of a prediction protocol for the screening of metabolic associated fatty liver disease in children with overweight or obesity
  948. Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease
  949. obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
  950. Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease
  951. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
  952. The association of dietary inflammatory index (DII) and central obesity with non-alcoholic fatty liver disease (NAFLD) in people with diabetes (T2DM)
  953. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
  954. Changes in the prevalences of obesity, abdominal obesity, and non-alcoholic fatty liver disease among Korean children during the COVID-19 outbreak
  955. Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity
  956. A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver …
  957. Growth hormone administration improves nonalcoholic fatty liver disease in overweight/obesity: a randomized trial
  958. Prebiotic inulin as a treatment of obesity related nonalcoholic fatty liver disease through gut microbiota: a critical review
  959. Nonalcoholic fatty liver disease and continuous metabolic syndrome in adolescents with overweight/obesity
  960. A systems biology approach to study non-alcoholic fatty liver (NAFL) in women with obesity
  961. Genetic predisposition, lifestyle risk, and obesity associate with the progression of nonalcoholic fatty liver disease
  962. Ferritin as a key risk factor for nonalcoholic fatty liver disease in children with obesity
  963. Waist-to-hip ratio and inflammatory parameters are Associated with risk of non-alcoholic fatty liver disease in patients with morbid obesity
  964. Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease
  965. Effects of different green teas on obesity and non-alcoholic fatty liver disease induced by a high-fat diet in mice
  966. … glucose-body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity
  967. Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity
  968. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease
  969. Dietary fiber intake and non-alcoholic fatty liver disease: The mediating role of obesity
  970. Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non‐alcoholic fatty liver disease and metabolic dysfunction
  971. Tomatidine ameliorates obesity-induced nonalcoholic fatty liver disease in mice
  972. obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
  973. Hidden Complication of obesity and Diabetes: Is It Time to Put More Focus on fatty liver?
  974. Pediatric obesity-related non-alcoholic fatty liver disease: waist-to-height ratio best anthropometrical predictor
  975. SLC6A14 deficiency is linked to obesity, fatty liver, and metabolic syndrome but only under conditions of a high-fat diet
  976. Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity
  977. A model incorporating serum alkaline phosphatase for prediction of liver fibrosis in adults with obesity and nonalcoholic fatty liver disease
  978. Nonalcoholic fatty liver disease in young children with obesity
  979. Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
  980. Role of fatty acid transport protein 4 in metabolic tissues: insights into obesity and fatty liver disease
  981. Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis
  982. Associations of serum fatty acid proportions with obesity, insulin resistance, blood pressure, and fatty liver: the cardiovascular risk in Young Finns Study
  983. Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study
  984. Association between sarcopenic obesity status and nonalcoholic fatty liver disease and fibrosis
  985. Endoscopic sleeve gastroplasty—Minimally invasive treatment for non-alcoholic fatty liver disease and obesity
  986. Trends in prediabetes and non-alcoholic fatty liver disease associated with abdominal obesity among Korean children and adolescents: based on the Korea …
  987. The challenging role of micro-RNAs in non-alcoholic fatty liver disease in children with obesity: is it time for a new era?
  988. Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity
  989. … predicts the development of Nonalcoholic fatty liver disease: is it irrespective to visceral adiposity index, visceral adipose tissue thickness and other obesity indices?
  990. Gender differences in the risk for incident non-alcoholic fatty liver disease according to the transition of abdominal obesity status: A 16-year cohort study
  991. Evaluation of liver Metabolism Biomarkers in Metabolic Associated fatty liver Disease According to obesity Phenotype
  992. Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring
  993. Frequency Of Occurrence of NonAlcoholic fatty liver Heptoses in Patients Without obesity
  994. Echinocystic acid prevents obesity and fatty liver via interacting with FABP1
  995. Role of branched-chain amino acid metabolism in type 2 diabetes, obesity, cardiovascular disease and non-alcoholic fatty liver disease
  996. Gut microbiota in obesity and nonalcoholic fatty liver disease
  997. Serum uric acid is a mediator of the association between obesity and incident nonalcoholic fatty liver disease: A prospective cohort study
  998. … combining the simple anthropometric obesity parameters, Body Mass Index (BMI) and a Body Shape Index (ABSI), to assess the risk of non-alcoholic fatty liver …
  999. obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated …
  1000. Association between sarcopenic obesity and nonalcoholic fatty liver disease and fibrosis detected by Fibroscan
  1001. Non‐alcoholic fatty liver disease mediates the effect of obesity on arterial hypertension
  1002. A prediction model of the incidence of nonalcoholic fatty liver disease with visceral fatty obesity: a general population-based study
  1003. Lower circulating leptin levels are related to non-alcoholic fatty liver disease in children with obesity
  1004. Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease
  1005. … AND CARBOHYDRATE METABOLISM IN PATIENTS WITH NON-ALCOHOLIC fatty liver DISEASE ON THE BACKGROUND OF ABDOMINAL obesity
  1006. Impact of weight reduction on thyroid function and nonalcoholic fatty liver among Egyptian adolescents with obesity
  1007. GATA3 as an immunomodulator in obesity-related metabolic dysfunction associated with fatty liver disease, insulin resistance, and type 2 diabetes
  1008. Models to predict non-alcoholic fatty liver disease linked to obesity in Morocco
  1009. Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease
  1010. Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: a randomized controlled trial
  1011. Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced obesity and Nonalcoholic fatty liver Disease in Mice
  1012. Substantiation of approaches to the correction of lipid metabolism disorders and non-alcoholic fatty liver disease in children with exogenous obesity
  1013. Identification of Hepatic Dendritic Cells in liver Biopsies in Patients with Metabolic Dysfunction-Associated fatty liver Diseas (MAFLD) and obesity
  1014. The association of sarcopenia and visceral obesity with lean nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus
  1015. Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet …
  1016. Polygonatum sibiricum polysaccharides protect against obesity and non-alcoholic fatty liver disease in rats fed a high-fat diet
  1017. Allele-specific variation at APOE increases nonalcoholic fatty liver disease and obesity but decreases risk of Alzheimer’s disease and myocardial infarction
  1018. Corn peptides improved obesity-induced non-alcoholic fatty liver disease through relieving lipid metabolism, insulin resistance and oxidative stress
  1019. The association between different obesity phenotypes and liver fibrosis scores in elderly individuals with fatty liver in Taiwan
  1020. Pregnane X receptor exacerbates nonalcoholic fatty liver disease accompanied by obesity-and inflammation-prone gut microbiome signature
  1021. Shenge Formula attenuates high-fat diet-induced obesity and fatty liver via inhibiting ACOX1
  1022. Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models
  1023. Soluble Polysaccharide Derived from Laminaria japonica Attenuates obesity-Related Nonalcoholic fatty liver Disease Associated with Gut Microbiota …
  1024. The relationship between lipid profile and non-alcoholic fatty liver disease in children and adolescents with obesity
  1025. Walnut green husk polysaccharides prevent obesity, chronic inflammatory responses, nonalcoholic fatty liver disease and colonic tissue damage in high-fat diet fed …
  1026. Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with obesity and Nonalcoholic fatty liver Disease
  1027. Combination of the effect of ginger and anti‐inflammatory diet on children with obesity with nonalcoholic fatty liver disease: A randomized clinical trial
  1028. obesity and non-alcoholic fatty liver disease: cardiometabolic risks and their correction
  1029. Expression of STING in Women with Morbid obesity and Nonalcoholic fatty liver Disease
  1030. fatty liver/Adipose Tissue Dual‐Targeting Nanoparticles with Heme Oxygenase‐1 Inducer for Amelioration of obesity, obesity‐Induced Type 2 Diabetes, and …
  1031. Obstructive sleep apnea syndrome risk in patients with non-alcoholic fatty liver disease is associated with obesity and presence of Nash
  1032. obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study
  1033. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity
  1034. Features of arterial hypertension combined with obesity according to non-alcoholic fatty liver disease (steatosis and steatohepatitis)
  1035. A case report of nonalcoholic fatty liver disease with obesity and dyslipidemia
  1036. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
  1037. Preventive effects of different black and dark teas on obesity and non-alcoholic fatty liver disease and modulate gut microbiota in high-fat diet fed mice
  1038. … Radix et Rhizoma Attenuates the Progress of obesity-Induced Non-Alcoholic fatty liver Disease through Modulating Intestinal Microbiota-Related Gut–liver …
  1039. Gut microbiota modulation as an alternative in the management of non-alcoholic fatty liver disease and obesity
  1040. Prevalence of overweight/obesity and its relationship with metabolic syndrome and fatty liver index in adult patients with type 1 diabetes. A Brazilian …
  1041. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease
  1042. Associations between abdominal obesity indices and pathological features of non‐alcoholic fatty liver disease: Chinese visceral adiposity index
  1043. Benefits of physical exercise as approach to prevention and reversion of non-alcoholic fatty liver disease in children and adolescents with obesity
  1044. Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated nonalcoholic fatty liver disease
  1045. obesity as an Additional Risk Factor for Thrombogenic Changes in Hemostasis in Hypertensive Patients with Non-Alcoholic fatty liver Disease
  1046. Improvement of obesity-induced fatty liver disease by intermittent hypoxia exposure in a murine model
  1047. obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease
  1048. Protective effect and mechanism of lactoferrin combined with hypoxia against high-fat diet induced obesity and non-alcoholic fatty liver disease in mice
  1049. Age‐dependent effects of diabetes and obesity on liver‐related events in non‐alcoholic fatty liver disease: Subanalysis of CLIONE in Asia
  1050. Lutein ameliorates high‐fat diet‐induced obesity, fatty liver, and glucose intolerance in C57BL/6J mice
  1051. Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice
  1052. Screening patterns of nonalcoholic fatty liver disease in children with obesity in Canadian primary care: A cross-sectional study
  1053. … scores based on fatty liver index, magnetic resonance imaging and lipidomic for a nutrigenetic personalized management of NAFLD: The fatty liver in obesity …
  1054. Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity
  1055. Metabolic Dysfunction–Associated fatty liver Disease (MAFLD) and Thyroid Function in Childhood obesity: A Vicious Circle?
  1056. Sarcopenic obesity in non-alcoholic fatty liver disease
  1057. NON-ALCOHOLIC fatty liver DISEASE IN obesity AND ALSTRÖM SYNDROME, AN ULTRA-RARE GENETIC MODEL FOR METABOLIC DISEASE
  1058. Effect of Ayurveda interventions in non-alcoholic grade II fatty liver associated with obesity–A case report
  1059. Pinch loss ameliorates obesity, glucose intolerance, and fatty liver by modulating adipocyte apoptosis in mice
  1060. Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity
  1061. The Role of Olfactomedin 2 in the Adipose Tissue–liver Axis and Its Implication in obesity-Associated Nonalcoholic fatty liver Disease
  1062. Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity
  1063. Analysis of risk factors for non-alcoholic fatty liver disease in hospitalized children with obesity before the late puberty stage
  1064. Antisense oligonucleotide technologies to combat obesity and fatty liver disease
  1065. Male Marfan mice are predisposed to high-fat diet-induced obesity, diabetes, and fatty liver
  1066. Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
  1067. BMAL1 deletion protects against obesity and non-alcoholic fatty liver disease induced by a high-fat diet
  1068. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis
  1069. … ASSOCIATED (FTO) RS17817449 GENE POLYMORPHISM WITH INSULIN RESISTANCE AND obesity IN THE PATIENTS WITH NON-ALCOHOLIC fatty liver …
  1070. Risk scores for metabolic dysfunction-associated fatty liver disease in pediatric obesity
  1071. … low-volume interval training improves nonalcoholic fatty liver disease fibrosis score and cardiometabolic health in adults with obesity and metabolic syndrome.
  1072. Chronic intermittent hypoxia exposure alternative to exercise alleviates high-fat-diet-induced obesity and fatty liver
  1073. Unravelling obesity and fatty liver Disease Mechanisms; Insights from Population-Based Omics Studies
  1074. Metabolic impact of MKP-2 upregulation in obesity promotes insulin resistance and fatty liver disease
  1075. KLHL3 deficiency in mice ameliorates obesity, insulin resistance, and nonalcoholic fatty liver disease by regulating energy expenditure
  1076. Fucoxanthin as a Phytochemical Anti-obesity and Antioxidant Remedy in Non-Alcoholic fatty liver Disease: A Systematic Review
  1077. LIFR-α-dependent adipocyte signaling in obesity limits adipose expansion contributing to fatty liver disease
  1078. Pericardial fat, thoracic peri-aortic adipose tissue, and systemic inflammatory marker in nonalcoholic fatty liver and abdominal obesity phenotype
  1079. The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease
  1080. … activator of nuclear factor-Kappa B ligand/receptor activator of nuclear factor-kappa B axis in obesity, type 2 diabetes mellitus, and nonalcoholic fatty liver …
  1081. Noninvasive fibrosis screening in fatty liver disease among vulnerable populations: impact of diabetes and obesity on FIB-4 score accuracy
  1082. Circulating PCSK7 level is independently associated with obesity, triglycerides level and fatty liver index in a general population without medication
  1083. Ramadan fasting model exerts hepatoprotective, anti-obesity, and anti-hyperlipidemic effects in an experimentally-induced nonalcoholic fatty liver in rats
  1084. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity
  1085. The obesity and nonalcoholic fatty liver disease mouse model revisited: liver oxidative stress, hepatocyte apoptosis, and proliferation
  1086. New murine model of alcoholic hepatitis in obesity-induced metabolic-associated fatty liver disease
  1087. obesity and Non Alcoholic fatty liver Disease in Females in tertiary care Hospital
  1088. Frequency of Different Grades of obesity in Females with Non Alcoholic fatty liver Disease
  1089. Abdomen fat and liver segmentation of CT scan images for determining obesity and fatty liver correlation
  1090. obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients
  1091. Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
  1092. obesity, non-alcoholic fatty liver disease, COVID-19: dangerous liaisons
  1093. Identification of New Non-BBB permeable tryptophan hydroxylase inhibitors for treating obesity and fatty liver disease
  1094. A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease
  1095. The incidence of visceral obesity in patients with arterial hypertension and non-alcoholic fatty liver disease
  1096. Is There Any Relationship Between Helicobacter pylori and obesity, Metabolic Syndrome, and Non-alcoholic fatty liver Disease?
  1097. A prediction model of liver fat fraction and presence of non-alcoholic fatty liver disease (NAFLD) among patients with overweight or obesity
  1098. Approach to Pediatric obesity and Nonalcoholic fatty liver Disease
  1099. The use of very low‐calorie diets in subjects with obesity complicated with nonalcoholic fatty liver disease: A scoping
  1100. … -like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver disease—current evidence
  1101. Adiponectin involved in portal flow hepatic extraction of 13C-methacetin in obesity and non-alcoholic fatty liver
  1102. Defective FXR-SHP Regulation in obesity Aberrantly Increases miR-802 Expression, Promoting Insulin Resistance and fatty liver
  1103. … Lifestyle intervention improves markers of Nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes and obesity: a retrospective matched …
  1104. The inhibition of inner mitochondrial fusion in hepatocytes reduces non-alcoholic fatty liver and improves metabolic profile during obesity by modulating bile acid …
  1105. Effects of GLP-1-Agonist Liraglutide on Non-alcoholic fatty liver disease and obesity
  1106. Association between alanine aminotransferase as surrogate of fatty liver disease and physical activity and sedentary time in adolescents with obesity
  1107. Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 …
  1108. ENDOTOXINEMIA IN PATIENTS WITH obesity AND NON-ALCOHOLIC fatty liver DISEASE
  1109. Association of C-reactive protein with histological, elastographic, and sonographic indices of non-alcoholic fatty liver disease in individuals with severe obesity
  1110. Adipose-targeted SWELL1 deletion exacerbates obesity-and age-related nonalcoholic fatty liver disease
  1111. Aqueous extract of Artemisia capillaris improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet
  1112. The Weighty Issue of Treating obesity in Patients With Nonalcoholic fatty liver Disease
  1113. Phenolic-rich smoothie consumption ameliorates non-alcoholic fatty liver disease in obesity mice by increasing antioxidant response
  1114. Association between fatty liver disease markers and physical activity and sedentary time in children and adolescents with obesity
  1115. QTL-mapping in the obese Berlin Fat Mouse identifies additional candidate genes for obesity and fatty liver disease
  1116. … Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic fatty liver Disease—Related Markers in Patients with obesity after Mini Gastric …
  1117. Cardiac Structure and Function in Patients With obesity and Non-alcoholic fatty liver Disease
  1118. Effects of Fish Oil Supplementation on Reducing the Effects of Paternal obesity and Preventing fatty liver in Offspring
  1119. Role of genetic modification of the PNPLA3 gene in predicting metabolically unhealthy obesity and metabolic associated fatty liver disease in children
  1120. Pharmacological interventions for obesity and non-alcoholic fatty liver disease: Grade evaluation of existing clinical evidence
  1121. Association between non-alcoholic fatty liver disease and subclinical hypothyroidism in children with obesity
  1122. … in Gadoxetate Disodium-Enhanced liver MRI as an Imaging Biomarker in the Diagnosis of Non-Alcoholic fatty liver Disease in Pediatric obesity
  1123. Non‐alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle
  1124. Nonalcoholic fatty liver Disease Severity Is Related to Plasma Pro-Oxidative Biomarkers Rather Than liver Tissue-Measured Nitrogen Metabolism Biomarkers in …
  1125. Environmental exposure to low-dose perfluorohexanesulfonate promotes obesity and non-alcoholic fatty liver disease in mice fed a high-fat diet
  1126. Prevalence of non-alcoholic fatty liver disease in adolescent boys and its association with obesity and lifestyle factors in rural Tamil Nadu
  1127. Soybean β-conglycinin: structure characteristic, allergenicity, plasma lipid-controlling, prevention of obesity and non-alcoholic fatty liver disease
  1128. obesity and Non-Alcoholic fatty liver Disease: Pathophysiology and Management Focused
  1129. Impact of gastric bypass surgery on the liver fibrosis of patients with extreme obesity and nonalcoholic fatty liver disease in 30-month follow-up
  1130. Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease
  1131. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism
  1132. Perchlorate exposure does not induce obesity or non-alcoholic fatty liver disease in zebrafish
  1133. Bariatric surgery for non-alcoholic fatty liver disease in individuals with obesity (Base-NAFLD): protocol of a prospective multicenter observational follow-up …
  1134. … effects of polyphenol enriched complex plants extract on metabolic dysfunctions associated with obesity and related nonalcoholic fatty liver diseases in high …
  1135. … -based association of coronary artery calcification and framingham risk score with non-alcoholic fatty liver disease and abdominal obesity in taiwanese adults …
  1136. obesity and Metabolic Dysfunction-associated fatty liver Disease: Understanding the Intricate Link
  1137. Effects of a Short-Term Meal Replacement Hypocaloric Diet in Subjects with obesity and High fatty liver Index
  1138. Cardiovascular and metabolic risks in patients with obesity and non-alcoholic fatty liver disease
  1139. Deoxyschizandrin ameliorates obesity and non‐alcoholic fatty liver disease: Involvement of dual Farnesyl X receptor/G protein‐coupled bile acid receptor 1 activation …
  1140. NLRP3 Deficiency in Nonimmune Cells Averts obesity-Induced fatty liver Disease
  1141. A significant association of non-obese non-alcoholic fatty liver disease with osteosarcopenic obesity in females 50 years and older
  1142. Low muscle mass is linked with presence of non-alcoholic fatty liver disease irrespective to central obesity: highlights from a prospective epidemiological study in …
  1143. Danning tablets alleviate high fat diet-induced obesity and fatty liver in mice via modulating SREBP pathway
  1144. Combined Amelioration of Prebiotic Resveratrol and Probiotic Bifidobacteria on obesity and Nonalcoholic fatty liver Disease
  1145. … of eating behaviour disorders, anthropometric and physiological indicators in patients with non-alcoholic fatty liver disease on the background of abdominal obesity
  1146. Plasma Adiponectin and Its Correlation with Carotid Intima-Media Thickness in obesity and in Type 2 Diabetes and Nonalcoholic fatty liver Disease
  1147. Maternal obesity accelerated non‑alcoholic fatty liver disease in offspring mice by reducing autophagy
  1148. Daisaikoto improves fatty liver and obesity in melanocortin-4 receptor gene-deficient mice via the activation of brown adipose tissue
  1149. Associations of lipid parameters with non-alcoholic fatty liver disease in type 2 diabetic patients according to obesity status and metabolic goal achievement
  1150. Ziziphus spina‐christi (L.) fortified with Camellia sinensis mediates apoptosis, Notch‐1 signaling, and mitigates obesity‐induced non‐alcoholic fatty liver
  1151. Dry powder microneedle-enabled transdermal anti-inflammatory therapy for obesity, diabetes, hyperlipidemia, and fatty liver
  1152. Differential metabolic risk factors of early nonalcoholic fatty liver disease in male adolescents with obesity and non-obesity prior to adulthood
  1153. Laparoscopic sleeve gastrectomy alters 1H-NMR-measured lipoprotein and glycoprotein profile in patients with severe obesity and nonalcoholic fatty liver …
  1154. Serum proteome profiling reveals differentially expressed proteins between subjects with metabolically healthy obesity and nonalcoholic fatty liver disease
  1155. … weight-loss intervention on metabolic, ultrasound and anthropometric parameters among patients with obesity and non-alcoholic fatty liver disease: an RCT
  1156. The Effect of Non-Alcoholic fatty liver Disease on Weight Loss and Resolution of obesity-Related Disorders After Bariatric Surgery
  1157. Significance of autoantibody seropositivity in children with obesity and non‐alcoholic fatty liver disease
  1158. Pyridylnidulin exerts anti-diabetic properties and improves non-alcoholic fatty liver disease in diet-induced obesity mice
  1159. … , and the risk of nonalcoholic fatty liver disease in individuals with metabolically healthy overweight or obesity and metabolically unhealthy overweight or obesity
  1160. LepRb+ cell–specific deletion of Slug mitigates obesity and nonalcoholic fatty liver disease in mice
  1161. … Secreted Frizzled-Related Protein 5 mRNA Expression in the Adipose Tissue of Women with Nonalcoholic fatty liver Disease Associated with obesity
  1162. Computed tomography–based gastric volumetry for morbid obesity to assess weight loss and fatty liver change
  1163. The role of mean platelet volume in nonalcoholic fatty liver disease without cardiovascular comorbidities, obesity and diabetes mellitus
  1164. Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR−/− mice
  1165. Deregulation of secreted Frizzled-related protein 5 in nonalcoholic fatty liver disease associated with obesity
  1166. Association of 24 h Behavior Rhythm with Non-Alcoholic fatty liver Disease among American Adults with Overweight/obesity
  1167. … -Binding Protein (LBP) Levels Are Associated with Non-Alcoholic fatty liver Disease (NAFLD) and Adipose Inflammation in Human obesity
  1168. fatty liver disease reverses the obesity paradox in chronic kidney disease stages 3–5: A follow‐up study of NHANES III
  1169. Tilianin protects against nonalcoholic fatty liver disease in early obesity mice
  1170. Non-alcoholic fatty liver disease and obesity among adult donors are major challenges to living-donor liver transplantation: A single-center experience
  1171. Structurally‐engineered fatty acid 1024 (SEFA‐1024) improves diet‐induced obesity, insulin resistance, and fatty liver disease
  1172. Psoas muscle area and paraspinal muscle fat in children and young adults with or without obesity and fatty liver
  1173. In silico profiling of nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on the treatment of non-alcoholic fatty liver disease
  1174. Investigating the effects of long-term Aroclor 1260 exposure on fatty liver disease in a diet-induced obesity mouse model
  1175. Comment on Leone et al. Association between Mediterranean Diet and fatty liver in Women with Overweight and obesity. Nutrients 2022, 14, 3771
  1176. Mendelian randomization explores the causal relationships between obesity, diabetes, inflammation and nonalcoholic fatty liver disease
  1177. Non-alcoholic fatty liver Disease in Pediatric obesity
  1178. Relationship of gut microbiota and immunological response in obesity-related non-alcoholic fatty liver disease in children
  1179. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: fatty liver in obesity (FLiO) Study
  1180. Comment on Leone et al. Association between Mediterranean Diet and fatty liver in Women with Overweight and obesity. Nutrients 2022, 14, 3771
  1181. Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults
  1182. Metabolic health phenotype better predicts subclinical atherosclerosis than body mass index-based obesity phenotype in the non-alcoholic fatty liver disease …
  1183. Early menarche is associated with insulin-resistance and non-alcoholic fatty liver disease in adolescents with obesity
  1184. … in pregnant women with non-alcoholic fatty liver disease at the stage of non-alcoholic steatohepatitis with varying degrees of comorbid obesity under the influence of …
  1185. Real-life prevalence of Metabolic Associated fatty liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a tertiary obesity clinic in Italy
  1186. Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight and obesity scales in 219,477 spanish workers
  1187. Effects of sleeve gastrectomy and Roux-en-Y gastric bypass on non-alcoholic fatty liver disease in Iranians with morbid obesity
  1188. Hepatopulmonary syndrome: a rare manifestation of cirrhosis in patient with diencephalic obesity and nonalcoholic fatty liver disease after surgery for …
  1189. Value of triglyceride-glucose index combined with obesity index in predicting nonalcoholic fatty liver disease in individuals with obstructive sleep apnea
  1190. Peripheral selective Oxadiazolylphenyl alanine derivatives as tryptophan hydroxylase 1 inhibitors for obesity and fatty liver disease
  1191. Development of a prediction protocol for the screening of metabolic associated fatty liver disease in children with overweight or obesity
  1192. Influence of surgical treatment of obesity on the course of nonalcoholic fatty liver disease
  1193. Effects of lifestyle intervention on IGF-1, IGFBP-3, and insulin resistance in children with obesity with or without metabolic-associated fatty liver disease
  1194. Main phylotypes of gut microbiota and their connection with the degree of obesity and the stage of liver fibrosis in patients with non-alcoholic fatty liver disease
  1195. … Protective Effects of Cinnamyl Alcohol Against Hepatic Steatosis, Oxidative and Inflammatory Stress in Nonalcoholic fatty liver Disease Induced by Childhood obesity
  1196. Comparison of obesity-Related Indicators for Nonalcoholic fatty liver Disease Diagnosed by Transient Elastography
  1197. Convergence of endobariatrics and endohepatology for evaluation and treatment of obesity and nonalcoholic fatty liver disease
  1198. The Association Between obesity, Nonalcoholic fatty liver Disease (NAFLD), and Diabetes
  1199. Synthesis and biological evaluation of xanthine derivatives with phenacyl group as tryptophan hydroxylase 1 (TPH1) inhibitors for obesity and fatty liver disease
  1200. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity
  1201. GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease
  1202. Bariatric surgery improves metabolic and nonalcoholic fatty liver disease markers in metabolically healthy patients with morbid obesity at 5 years
  1203. A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in men with obesity
  1204. Non-Alcoholic fatty liver Disease in Children with Overweight and obesity
  1205. Trappc9 deficiency causes obesity and fatty liver disease by constraining dopamine neurotransmission
  1206. Association of Aquaporin 7 and 9 with obesity and fatty liver in db/db Mice
  1207. Deleted genes associated with obesity in Mexican patients diagnosed with nonalcoholic fatty liver disease
  1208. … STEATOSIS, obesity, AND INSULIN-RESISTANCE IN ADULTS WITH NON-ALCOHOLIC fatty liver DISEASE UNDERGOING THE PRIMARY obesity …
  1209. Autoantibodies in children with overweight and obesity with nonalcoholic fatty liver disease: the major role of laboratory technique
  1210. … to Alvarez Stehle, E. Comment on “Leone et al. Association between Mediterranean Diet and fatty liver in Women with Overweight and obesity. Nutrients 2022, 14 …
  1211. Comparative Evaluation of Serum Copeptin in obesity with Non Alcoholic fatty liver Disease.
  1212. Omega-3 use for the treatment of hypertriglyceridemia, low high-density lipoprotein cholesterol levels, and nonalcoholic fatty liver disease in children with obesity
  1213. Usefulness of the triglyceride glucose index to predict nonalcoholic fatty liver disease in children with obesity
  1214. … between nonalcoholic fatty liver disease with visceral fat depots of other localization, metabolic parameters and markers of renal dysfunction in patients with obesity
  1215. Non-Alcoholic fatty liver in obesity with Deteriorating Glucose Control
  1216. Peony seed oil protects against obesity-induced non-alcoholic fatty liver disease via modulation of endoplasmic reticulum stress
  1217. Relationship between plasma 12, 13-diHOME level and nonalcoholic fatty liver disease in patients with type 2 diabetes and obesity.
  1218. … fecal viromes improve blood glucose regulation and alleviates symptoms of metabolic dysfunction-associated fatty liver disease in an obesity male mouse model
  1219. Cardiovascular and liver Diseases in Subjects With Sarcopenic obesity and Nonalcoholic fatty liver Disease
  1220. Reply to letter:“RE: Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study”
  1221. Risk Stratification for Sarcopenic obesity in Nonalcoholic fatty liver Disease
  1222. The association between obesity measurement indices and nonalcoholic fatty liver disease
  1223. SAT356 Predicting Nonalcoholic fatty liver Disease in Adolescent Girls with Polycystic Ovary Syndrome and obesity
  1224. Sarcopenic obesity, the Possible Culprit for Nonalcoholic fatty liver Disease or Fibrosis
  1225. Mediterranean diet is inversely associated to fatty liver index in patients with obesity and low HDL-cholesterol
  1226. Gender difference in association between low muscle mass and risk of non-alcoholic fatty liver disease among Chinese adults with visceral obesity
  1227. Detecting non-alcoholic fatty liver in children with owerweight and obesity.
  1228. Morbid obesity Associated with Non-Alcoholic fatty liver Disease and Complicated by Severe Non-Cirrhotic Portal Hypertension: A Case Report from Rural Kenya
  1229. Developmental programming of Kupffer cells by maternal obesity causes fatty liver disease in the offspring
  1230. Liraglutide with lifestyle intervention in adolescents with overweight/obesity, nonalcoholic fatty liver disease, and type II diabetes mellitus
  1231. A novel PKCβ inhibitor more potent than ruboxistaurin: potential therapeutic tool for obesity and fatty liver disease
  1232. Association between muscle mass deficits and the non-alcoholic fatty liver disease fibrosis score in adults without central obesity
  1233. Non-alcoholic fatty liver disease (NAFLD) and obesity in inflammatory bowel disease (IBD) patients in Gorgan
  1234. Clinical efficacy of laparoscopic sleeve gastrectomy in treatment of obesity associated nonal-coholic fatty liver disease
  1235. liver microRNA transcriptome reveals miR-182 as link between type 2 diabetes and fatty liver disease in obesity
  1236. Study on the effect of vitamin D on obesity and fatty liver induced by monosodium glutamate in male albino rats
  1237. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating obesity Medicine for Treatment of Nonalcoholic fatty liver Disease
  1238. Arterial stiffness, high fasting glucose, and fatty liver as predictors for visceral obesity in middle-aged Chinese individuals: a cross-sectional study
  1239. Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in obesity-related fatty liver disease
  1240. Very low-carbohydrate ketogenic diet for the treatment of severe obesity and associated non-alcoholic fatty liver disease: the role of sex differences
  1241. Usefulness of Controlled Attenuation Parameter for Identification and Grading of Nonalcoholic fatty liver Disease in Adolescents with obesity
  1242. Risk Stratification for Sarcopenic obesity in Subjects With Nonalcoholic fatty liver Disease Q1
  1243. … Between Metabolic Dysfunction-Associated fatty liver Disease and Hyperfiltration In Subjects with Prediabetes and Abdominal obesity Without Evidence of Chronic …
  1244. Focal nodular hyperplasia‐like lesion in a girl with obesity and fatty liver
  1245. Validation of Nutritional Ultrasound as a Tool for the Detection of Risk of Non-Alcoholic fatty liver Disease in the Pediatric Population with obesity
  1246. The natural course of liver fibrosis in non-alcoholic fatty liver disease and after chronic hepatitis C cure in patients with normal body weight and obesity
  1247. Association between Dietary fatty Acid Intake and liver Steatosis and Fibrosis in a Sample of Mexican-Origin Hispanic Adults with Overweight or obesity
  1248. TyG index correlation with surrogate measures of visceral obesity, insulin resistance and non-alcoholic fatty liver disease
  1249. … Efficacy of Using Liraglutide for Improving Non-Acoholic fatty liver Disease Condition in Pediatric-Adolescent Population with obesity: Real World Evidence
  1250. Mesenchymal Stromal Cell (MSC) Therapy Improve Nonalcoholic fatty liver Disease (NAFLD) in Long Term high Fat Diet (HFD) Induced obesity (DIO) Mouse
  1251. Markedly Low Prevalence of fatty liver despite obesity in Prader-Willi Syndrome: A Search for Protective Genetic Markers
  1252. Association between obesity profile and non-alcoholic fatty liver by race/ethnicity
  1253. Inhibition of Forebrain Microglia Ameliorates Non‐alcoholic fatty liver Disease During obesity
  1254. … multivariable Mendelian randomization analysis disentangling the causal relations between abdominal obesity, non-alcoholic fatty liver disease and cardiometabolic …
  1255. Ficus Lyrata Bark Extract Alleviates Steatosis in obesity-Induced Non-Alcoholic fatty liver Disease in Rats
  1256. Optimization of early diagnosis of fibrosis in patients with non-alcoholic fatty liver disease with obesity and overweight
  1257. Chronic Transient Hypoxia Alleviates High Fat Diet-Induced obesity and fatty liver in C57 Mice by Upregulating Epinephrine Levels and Activation of AMPK
  1258. Fatal complications after an interrupted gastric bypass operation in a patient with non-alcoholic fatty liver disease and massive obesity: a case report
  1259. A Promising Approach for Preventing of Diet-Induced obesity and fatty liver Using Tetrahydroxanthohumol, A Synthetic Derivative of Xanthohumol
  1260. RE: Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity—an observational study
  1261. 372-OR: Long-Term Outcomes of Metabolic Surgery vs. Medical/Lifestyle Therapy on Nonalcoholic fatty liver Disease in Adults with obesity and Type 2 Diabetes
  1262. B Cell Responses During obesity-Associated Non-Alcoholic fatty liver Disease and Age-Related Decline
  1263. obesity–fatty liver: the role of the pediatrician
  1264. Usе of plant-based drugs in the treatment of nonalcoholic fatty liver disease and obesity
  1265. Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight and obesity scales in 219,477 spanish workers
  1266. Is non-alcoholic fatty liver disease a consequence of obesity and a predictor of diabetes?
  1267. TLT-1, a Potential Regulator of Inflammatory Pathogenesis in obesity and Non-Alcoholic fatty liver Disease (NAFLD)
  1268. Cardiovascular pathology in patients with non-alcoholic fatty liver disease with overweight and obesity
  1269. obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver
  1270. Bifidobacterial probiotics protect mice from diet-induced obesity and fatty liver disease
  1271. obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study.
  1272. Relationship between metabolically healthy obesity and the prevalence of non-alcoholic fatty liver disease
  1273. Association between maternal obesity, essential fatty acids and biomarkers of fetal liver function
  1274. Non-alcoholic fatty liver disease (NAFLD) in children with obesity: narrative review and research gaps
  1275. Importance of the Gut-liver Axis on Lipid Metabolism: Implications in the Pathogenesis of obesity-Related Non-Alcoholic fatty liver Disease
  1276. 1348-P: Roux-en-Y Gastric Bypass Prevents obesity-Induced fatty liver by Modulating liver Lipocalin Type Prostaglandin D2 Synthase Expression
  1277. The Correlation of Diagnosed fatty liver and Hematological Examination and obesity Index in Adult Men
  1278. Elevated Plasma Copeptin Levels Identify the Presence and Severity of Nonalcoholic fatty liver Disease in obesity
  1279. The course of chronic kidney disease (chronic pyelonephritis) in patients with non-alcoholic fatty liver disease and obesity
  1280. Impact of gastric bypass surgery on the liver fibrosis of patients with extreme obesity and nonalcoholic fatty liver disease in 30-month follow-up.
  1281. Ionic Detoxification Ameliorates obesity and Reduces fatty liver in Rats Exposed to a High-Fat Diet
  1282. Forebrain microglia involvement in non‐alcoholic fatty liver disease during obesity
  1283. The role of microRNA-802 regulated by the nuclear receptor FXR-SHP cascade in obesity and non-alcoholic fatty liver disease
  1284. Deleterious liver-adipose crosstalk in obesity: Hydroethanolic extract of Lampaya medicinalis Phil.(Verbenaceae) counteracts fatty acid-induced fibrotic marker …
  1285. … implementation of a weight loss intervention pathway for non-alcoholic fatty liver disease patients by advanced practice hepatology providers with obesity …
  1286. … for Early Diagnosis of Kidney Damage in Patients with Type 2 Diabetes Combined with Nonalcoholic fatty liver Disease and obesity Exposed to Covid-19 …
  1287. Corrigendum to ‘Adiponectin involved in portal flow hepatic extraction of 13C-methacetin in obesity and non-alcoholic fatty liver.'[European Journal of Internal …
  1288. The diagnostic values of obesity-related indices in nonalcoholic fatty liver disease.
  1289. … with Anthropometric Measurements, Biochemical Parameters and Body Fat Distribution and the Effects of These Variables on fatty liver in Boys with obesity and …
  1290. Characterization of Chinese medicine celastrol and celastrol-loaded biodegradable nanoparticles towards the therapy of obesity and non-alcoholic fatty liver disease
  1291. Hepatic Insulin Resistance Drives Visceral obesity and Non-Alcoholic fatty liver Disease
  1292. Associations between dyspepsia and obesity in non-alcoholic fatty liver disease patients
  1293. Microbiome Relationship of gut microbiota and immunological response in obesity-related non-alcoholic fatty liver disease in children.
  1294. … omega-3 polyunsaturated fatty acids supplementation for liver left lateral section volume reduction in individuals with morbid obesity undergoing bariatric surgery: A …
  1295. Association of fat mass-and obesity-associated gene (FTO) polymorphisms with susceptibility to nonalcoholic fatty liver disease
  1296. obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients
  1297. obesity, non-alcoholic fatty liver disease, and FTO oligonucleotide polymorphism
  1298. INTENSITY OF MECHANISMS OF INTERACTION OF NON-ALCOHOLIC fatty liver DISEASE AND CHRONIC KIDNEY DISEASE AGAINST obesity
  1299. Corrigendum to ‘Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the liver (AISF), the Italian …
  1300. Metabolic fatty liver disease linked to obesity in burkinabè adults.
  1301. Lipid Droplet Accumulating Microglia Involvement In Non-Alcoholic fatty liver Disease During obesity
  1302. Central obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients with Non-alcoholic fatty liver Disease (NAFLD)
  1303. 210-OR: Presence of Type 2 Diabetes (T2D) Affects HDL Particle Proteomic Composition Independently of obesity or fatty liver
  1304. Laparoscopic sleeve gastrectomy in the treatment of obesity with nonalcoholic fatty liver disease
  1305. Correction: Non‑alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the liver (AISF), the Italian Society of …
  1306. obesity, Non-Alcoholic fatty liver Disease and Eating Behavior Disorders
  1307. … of the Italian Association for the Study of the liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of obesity (SIO)”[Dig liver Dis 54 (2022) 170 …
  1308. fatty acid binding protein 4 in obesity related liver disease; from steatosis to cancer progression
  1309. Correction: Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the liver (AISF), the Italian Society of …
  1310. 8-OR: Plasminogen Deficiency Protects against Nonalcoholic fatty liver Disease and Insulin Resistance, but Not Diet-Induced obesity
  1311. Semaglutide in obesity and Non-Alcoholic fatty liver Disease
  1312. … -Like Peptide-1 Receptor Agonists in the Treatment of obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic fatty liver Disease-Current Evidence
  1313. Inhibition of mammalian mtDNA transcription paradoxically activates liver fatty acid oxidation to reverse diet-induced hepatosteatosis and obesity
Related Posts

Inflammaging

Inhibits Lipid Droplet Accumulation

Xenobiotics

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping